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Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system. The mechanisms leading to development of MS are poorly understood, 
but the requirement for both genetic susceptibility factors and environmental 
factors has been demonstrated. Current genetic findings suggest that MS is 
primarily driven by immunological mechanisms, but the cell populations and 
pathways involved remain to be identified.
The aim of this thesis was to discover new MS-related genes and cellular 
pathways by testing genetic variants in selected candidate genes and by 
investigating gene expression on a genome-wide scale. It is shown that genes 
with altered expression in MS are associated with pathways related to certain 
T cell subpopulations. In addition, highly elevated levels of DEFA1A3 in MS were 
found, which together with findings in other diseases would suggest a role for 
this neutrophil-secreted defense molecule in autoimmune disease pathogene-
sis. Finally, genetic association at a previously suggested variant near one of the 
genes with altered expression in MS, CXCR4, was replicated, and preliminary 
evidence was found for correlation between this variant and CXCR4 expression.
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Abstract 
Anu Kemppinen, Studies on Causes of Multiple Sclerosis: From Genes to 
Transcriptome. National Institute for Health and Welfare (THL), Research 65/2011, 
153 pages. Helsinki, Finland 2011. 
ISBN 978-952-245-489-8 (printed), ISBN 978-952-245-490-4 (pdf) 
 
Multiple sclerosis (MS) is the most common cause of neurological disability in 
young adults, affecting more than two million people worldwide. It manifests as a 
chronic inflammation in the central nervous system (CNS) and causes demyelination 
and neurodegeneration. Depending on the location of the demyelinated plaques and 
axonal loss, a variety of symptoms can be observed including deficits in vision, 
coordination, balance and movement. With a typical age of onset at 20-40 years, the 
social and economic impacts of MS on lives of the patients and their families are 
considerable. Unfortunately the current treatments are relatively inefficient and the 
development of more effective treatments has been impeded by our limited 
understanding of the causes and pathogenesis of MS. 
 
Risk of MS is higher in biological relatives of MS patients than in the general 
population. Twin and adoption studies have shown that familial clustering of MS is 
explained by shared genetic factors rather than by shared familial environment. 
While the involvement of the human leukocyte antigen (HLA) genes was first 
discovered four decades ago, additional genetic risk factors have only recently been 
identified through genome-wide association studies (GWAS). Current evidence 
suggests that MS is a highly polygenic disease with perhaps hundreds of common 
variants with relatively modest effects contributing to susceptibility. Despite 
extensive research, the majority of these risk factors still remain to be identified. 
 
In this thesis the aim was to identify novel genes and pathways involved in MS. 
Using genome-wide microarray technology, gene expression levels in peripheral 
blood mononuclear cells (PBMC) from 12 MS patients and 15 controls were 
profiled and more than 600 genes with altered expression in MS were identified. 
Three of five selected findings, DEFA1A3, LILRA4 and TNFRSF25, were 
successfully replicated in an independent sample. Increased expression of DEFA1A3 
in MS is a particularly interesting observation, because its elevated levels have 
previously been reported also in several other autoimmune diseases.  
 
A systematic review of seven microarray studies was then performed leading to 
identification of 229 genes, in which either decreased or increased expression in MS 
had been reported in at least two studies. In general there was relatively little overlap 
across the experiments: 11 of the 229 genes had been reported in three studies and 
only HSPA1A in four studies. Nevertheless, these 229 genes were associated with 
several immunological pathways including interleukin pathways related to type 2 
and type 17 helper T cells and regulatory T cells. However, whether these pathways 
are involved in causing MS or related to secondary processes activated after disease 
onset remains to be investigated. The 229 genes were also compared with loci 
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identified in published MS GWASs. Single nucleotide polymorphisms (SNP) in 17 
of the 229 loci had been reported to be associated with MS with P-value <0.0001 
including variants in CXCR4 and SAPS2, which were the only loci where evidence 
for correlation between the associated variant and gene expression was found. The 
CXCR4 variant was further tested for association with MS in a large case-control 
sample and the previously reported suggestive association was replicated (P-value 
=0.0004). 
 
Finally, common genetic variants in candidate genes, which had been selected on the 
basis of showing association with other autoimmune diseases (MYO9B) or showing 
differential expression in MS in our study (DEFA1A3, LILRA4 and TNFRSF25), 
were tested for association with MS, but no evidence of association was found. 
 
In conclusion, through a systematic review of genome-wide expression studies in 
MS we have identified several promising candidate genes and pathways for future 
studies. In addition, we have replicated a previously suggested association of a SNP 
variant upstream of CXCR4 with MS. 
 
Keywords: autoimmune disease, common variant, CXCR4, DEFA1A3, HSPA1A, 
gene expression, genetic association, GWAS, MS, multiple sclerosis, systematic 
review 
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Terveyden ja hyvinvoinnin laitos, (THL), Tutkimus 65/2011, 153 sivua. Helsinki 
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ISBN 978-952-245-489-8 (printed), ISBN 978-952-245-490-4 (pdf) 
 
Pesäkekovettumatauti eli multippeli skleroosi (MS) on nuorten aikuisten yleisin 
neurologisiin häiriöihin johtava syy. Maailmanlaajuisesti sitä sairastaa yli kaksi 
miljoonaa ihmistä. Tauti ilmenee keskushermoston kroonisena tulehduksena ja 
johtaa myeliinikatoon ja keskushermoston rappeutumiseen. Oireet riippuvat 
leesioiden sijainnista keskushermostossa ja saattavat kohdistua esimerkiksi 
näköaistiin, tasapainoon ja koordinaatio- ja liikuntakykyyn. MS-tauti puhkeaa 
yleensa 20-40 vuoden iässä, joten sen sosiaaliset ja ekonomiset vaikutukset 
potilaisiin ja näiden lähimmäisiin ovat merkittävät. Tehokkaiden hoitojen 
kehittämistä on vaikeuttanut se, että taudin syyt ja mekanismit tunnetaan toistaiseksi 
huonosti. 
 
Todennäköisyys sairastua MS-tautiin on suurempi MS-potilaiden biologisilla 
sukulaisilla kuin populaatiossa keskimäärin. Kaksos- ja adoptiotutkimuksissa on 
osoitettu, että taudin keskittyminen perheisiin selittyy jaetuilla perinnöllisillä 
alttiustekijöillä. Vaikka immunologisiin soluihin liittyvien HLA-varianttien yhteys 
MS-tautiin osoitettiin jo lähes neljä vuosikymmentä sitten, uusia geneettisiä 
alttiustekijöitä on onnistuttu paikantamaan vasta viime vuosina koko genomin 
laajuisten assosiaatiotutkimusten avulla. Nykyisten tutkimusten valossa MS-
alttiuteen vaikuttavia geenivariantteja näyttäisi kuitenkin olevan jopa satoja ja suurin 
osa näistä on edelleen tunnistamatta. 
 
Tämän väitöskirjan tavoitteena oli tunnistaa uusia MS-tautiin liittyviä geenejä ja 
reaktioreittejä. Geenien ilmentymistasoja verrattiin ensin periferaalisissa 
mononukleaarisissa immuunisoluissa MS-potilaiden ja verrokkien välillä käyttäen 
mikrosirutekniikkaa, joka mahdollistaa kaikkien tunnettujen geenien samanaikaisen 
tarkastelun. Yli 600 geenin ilmentymisen havaittiin poikkeavan merkitsevästi MS-
potilaiden ja verrokkien välillä. Tunnistetuista geeneistä viisi valittiin 
toistotutkimukseen, jossa kolmen geenin (DEFA1A3, LILRA4 ja TNFRSF25) 
tapauksessa ilmentymisero potilaiden ja verrokkien välillä toistui. Näistä geeneistä 
DEFA1A3 on erityisen kiinnostava, sillä sen ilmentymistason on havaittu olevan 
verrokkeja korkeampi myös muissa autoimmuunisairauksissa. 
 
Koska vastaavia mikosirututkimuksia on tehty MS-taudissa myös aiemmin, yhtenä 
väitöskirjan tavoitteena oli verrata tuloksia näistä tutkimuksista. Vertailuun otettiin 
kaikkiaan seitsemän tutkimusta, mukaan lukien tämän väitöskirjan osana tehty 
tutkimus. Tavoitteena oli tunnistaa geenit, joissa ilmentymisen oli raportoitu 
poikkeavan MS-potilaiden ja verrokkien välillä ainakin kahdessa tutkimuksessa. 
Vaikka tällaisia geenejä tunnistettiin 229, yleisesti ottaen tutkimustulosten välillä oli 
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kuitenkin vähän päällekkäisyyttä: vain 11 geeniä oli raportoitu kolmessa 
tutkimuksessa ja ainoastaan yksi, HSPA1A, neljässä tutkimuksessa. 
Reaktioreittianalyysin avulla osoitettiin, että tunnistetut 229 geeniä assosioituvat 
merkittävästi useisiin mielenkiintoisiin immunologisiin reaktioreitteihin. Monet 
näistä liittyvät tiettyihin T-solutyppeihin, joiden merkitystä sekä MS-taudin alttiuden 
että taudin etenemisen ja patogeneesin kannalta on tulostemme perusteella syytä 
tutkia lisää.  
 
229 geenistä ainoastaan 17 on aiemmin raportoitu assosioituvan MS-tautiin, mikä 
viittaisi siihen että nämä 229 geeniä eivät välttämättä ole merkittäviä taudin 
alttiuden lisäämisen kannalta, mutta voivat liittyä taudin mekanismeihin taudin 
puhkeamisen jälkeen. 17 geenistä ainoastaan SAPS2- ja CXCR4-geenien tapauksessa 
havaitsimme yhteyden geenin ilmentymisen ja geneettisen riskivariantin välillä siten, 
että molemmissa tapauksissa geenin ilmentyminen oli koholla riskialleelin kantajilla.  
 
Lopuksi väitöskirjassa testattiin tämän CXCR4-lokuksessa sijaitsevan variantin 
assosiaatiota MS-tautiin tuhansien henkilöiden potilas-kontrolli aineistossa ja 
aiemmissa tutkimuksissa havaittu assosiaatio toistettiin (P-arvo =0.0004). Lisäksi 
tutkittiin valituissa ehdokasgeeneissä sijaitsevien yleisten geneettisten varianttien 
yhteyttä MS-tautiin. Edellä mikrosirututkimuksessa tunnistettujen DEFA1A3-, 
LILRA4- ja TNFRSF25-geenien lisäksi tarkasteltiin MYO9B-geeniä, jonka oli 
aiemmin havaittu assosioituvan muihin autoimmuunisairauksiin. Merkitsevää 
yhteyttä MS-taudin ja tarkasteltujen geneettisten varianttien välillä ei kuitenkaan 
havaittu. 
 
Yhteenvetona, tässä väitöskirjassa on geenien ilmentymistutkimusten ja niiden 
systemaattisen katsauksen avulla tunnistettu useita lupaavia ehdokasgeenejä (mm. 
DEFA1A3, LILRA4, TNFRSF25 ja HSPA1A) ja erityisesti T-soluihin liittyviä 
reaktioreittejä. Lisäksi väitöskirjassa on toistettu aiemmin raportoitu assosiaatio MS-
taudin ja CXCR4-lokuksessa sijaitsevan geneettisen variantin välillä. Tunnistettujen 
geenien rooli MS-taudin patogeneesissä on kuitenkin toistaiseksi tuntematon, joten 
tarkempia jatkotutkimuksia tarvitaan. 
 
Avainsanat: CXCR4, DEFA1A3, HSPA1A, geenien ilmentyminen, geneettinen 
assosiaatio, GWAS, MS-tauti, multippeli skleroosi, pesäkekovettumatauti, yleinen 
variantti  
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1 Introduction 
Multiple sclerosis (MS) is the most common cause of neurological disability in 
young people, affecting approximately 0.1% of individuals in populations of 
Northern European ancestry (Sadovnick and Ebers 1993, Dean 1994). Although the 
range in age of onset is broad, there is a peak at 20-40 years and MS therefore often 
has major economic and social impacts on lives of the patients and their families. 
MS manifests in the central nervous system (CNS) as demyelinated lesions in the 
myelin sheath and is also characterized by axonal loss. Myelin, or white matter, 
surrounds and protects the axons and is required for efficient transmission of nerve 
impulses. As a result of demyelination, scar tissue (”sclerosis”) is formed at various 
places in CNS (”multiple”). Depending on the locations of the lesions and axonal 
loss, a variety of symptoms can be observed (Figure 1). 
 
Currently available MS treatments can only slow the progression of the disease and 
are not effective in all patients. More effective treatments are therefore needed, but 
their development has been hindered by poor understanding of MS pathogenesis. 
Twin and adoption studies have provided evidence for a significant genetic 
component in MS predisposition and identifying genetic factors involved could 
therefore increase the understanding of underlying disease processes. Furthermore, 
as the environmental factors contributing to MS remain unknown, genetic research 
is perhaps more critical in MS than in complex disorders where controllable life 
style factors such as diet are known to play a significant role. However, as in other 
complex disorders, identifying MS predisposing genetic variants has proven to be a 
challenging task and for nearly four decades the Major Histocompatibility Complex 
(MHC) locus remained the only well-established genetic finding. 
 
At the time of starting this thesis in 2005, researchers were hopeful that association 
studies on selected candidate genes would detect common variants predisposing to 
complex diseases. This was also one of the approaches taken in this thesis. However, 
six years later it is easy to conclude that most of these early candidate gene studies 
had a low chance of succeeding for two main reasons. First, picking candidate genes 
is challenging when the disease mechanisms are poorly understood. This issue has 
been resolved thanks to advancements in genotyping technologies, which now allow 
high resolution genome-wide association studies (GWAS) of common single 
nucleotide polymorphism (SNP) variants at a manageable cost. Second, common 
variants have proven to have lower effects on disease risk than perhaps initially was 
thought. Consequently extensive sample sizes are required to achieve sufficient 
power for detecting associations. International collaborations have therefore become 
a necessity, with possibly one of the most impressive examples in complex diseases 
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being the International Multiple Sclerosis Genetics Consortium (IMSGC), which 
now has samples from ~20,000 MS patients from fourteen countries. As a result of 
the aforementioned technical advancements and collaborative efforts close to 50 
confirmed MS risk loci have been identified over the last four years. 
 
But despite the rapid recent progress, the genetic architecture of MS is far from 
unraveled. Even with the now long list of confirmed risk variants, much of the 
heritability of MS still remains unexplained. As the costs of next generation 
sequencing technologies are decreasing, the focus in the next years is likely to be on 
rare variants with potentially larger individual effects. In addition, most of the 
associated loci extend over several genes and further genetic and functional studies 
are needed in order to identify the real culprits in these regions, and to explore how 
they actually cause increased risk for MS. Since many risk variants are likely to 
affect gene expression studies, correlating genetic variants with expression of their 
nearby genes is one way of identifying the most likely disease-related genes. 
Genome-wide expression profiling and comparison with GWAS findings was also 
one of the approaches taken in this thesis. 
 
 
 
 
 
Figure 1. Common symptoms and functions affected in MS. Leonardo Da Vinci's 
“Vitruvian man” modified from a figure from Wikimedia commons. 
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2 Review of the literature 
2.1 Multiple sclerosis 
2.1.1 History, diagnosis and treatment 
 
The first documentation of MS may date back to a medieval Norse saga from the 
end of 11th century, which describes a woman, Halladora, with symptoms 
reminiscent of MS (Poser 1995, Holmøy 2006). A Scottish physician and artist 
Robert Carswell was knowingly the first to describe and illustrate spinal cord lesions 
in a post-mortem subject who was described as having been paralysed (Carswell 
1838), likely as a consequence of MS. The clinical features and pathology of MS 
(French sclérose en plaques) were, however, first systematically and 
comprehensively described by a French neurologist, Jean-Martin Charcot in the 19th 
century (Charcot 1865, 1868a, 1868b, 1868c). Today, the diagnosis of MS is based 
on Poser's criteria (Poser et al. 1983) or McDonald's criteria (McDonald et al. 2001, 
Polman et al. 2005), the latter of which incorporated direct detection of lesions 
through magnetic resonance imaging (MRI) (Table 1). 
 
Majority of patients initially present with a relapsing-remitting MS (RRMS), in 
which relapses are followed by partial or complete recovery. Around 65% of RRMS 
patients later proceed to secondary progressive MS (SPMS), in which the condition 
is chronic and deteriorating without intervening remission periods (Compston and 
Coles 2002). Around 20% of all MS cases show continuous progression from the 
onset, displaying primary-progressive MS (PPMS) (Compston and Coles 2002). The 
severity of MS is commonly measured on the Expanded Disability Status Scale 
(EDSS) from 0.0-10.0 (Kurtzke 1983). However, the EDSS score alone is not 
informative of the rate of progression. Multiple sclerosis severity score (MSSS), 
which is based on the EDSS score but also takes into account the time from onset, 
was therefore developed and can be used to predict the patient's approximate 
disability level after 30 years with MS (Roxburgh et al. 2005). 
 
Current MS treatments, such as interferon (IFN)-beta, natalizumab, glatiramer 
acetate and mitoxantrone, are immunomodulatory; they can decrease the 
inflammatory reaction, but do not directly protect against demyelination or 
neurodegeneration. They are also inefficient in treating progressive MS. 
Encouraging results in clinical trials have been obtained with rituximab, which 
targets B-cells (Chaudhuri and Behan 2008, De Palma and Sementa 2008, Schrijver 
2008), and alemtuzumab (CAMMS223 Trial Investigators et al. 2008), which is an 
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antibody against CD52, a surface protein present on lymphocytes and monocytes. 
However, both can have serious side effects. Some patients treated with rituximab 
have become affected with a usually fatal demyelinating disease, progressive 
multifocal leukoencephalopathy (PML) (Freim Wahl et al. 2007). After 
alemtuzumab treatment infection-associated events were reported in 66% of the 
patients, while autoimmune-related thyroid disorders and immune thrombocytopenic 
purpura developed in 23% and 3% of patients, respectively (CAMMS223 Trial 
Investigators et al. 2008). 
 
Table 1. McDonald's criteria for MS diagnosis. CSF=cerebrospinal fluid. 
VPE=visual evoked potential. Positive CSF refers to presence of oligoclonal 
immunoglobulin bands in CSF. While oligoclonal bands are characteristic for MS, 
their relevance for MS pathogenesis is not understood. Delayed VPE, i.e. delayed 
neurological response to a visual signal, is typical for MS. 
 
Clinical Presentation Additional Data Needed 
Two or more attacks and objective clinical 
evidence of two or more lesions separated in 
time and necessarily separated in space 
None 
Two or more attacks and objective clinical 
evidence of one lesion 
 
Dissemination in space demonstrated by 
 MRI 
or 
two or more MRI-detected lesions consistent 
with MS plus positive CSF 
or 
await further clinical attack implicating a 
different site 
One attack and objective clinical evidence of 
two or more lesions 
 
Dissemination in time demonstrated by  
MRI 
orsecond clinical attack 
One attack and objective clinical evidence of 
one lesion (clinically isolated syndrome) 
 
 
Dissemination in space demonstrated by  
MRI 
or 
two or more MRI-detected lesions consistent 
with MS plus positive CSF 
and 
dissemination in time demonstrated by 
MRI 
or 
second clinical attack 
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2.1.2 Pathogenesis 
 
Role of autoimmunity 
 
Although direct evidence is lacking, MS is commonly considered to be an 
autoimmune disease. Myelin proteins (myelin basic protein (MBP), myelin 
oligodendrocyte protein (MOG), proteolipid protein (PLP)) are obvious candidates 
for auto-antigens in MS, but their role as such has not been unequivocally 
demonstrated. However, MS displays characteristics typical for autoimmune 
disorders such as having a higher prevalence in females and showing strong linkage 
and association with the MHC locus. Although the precise role of MHC in these 
diseases is not understood, MHC encodes several molecules involved in antigen 
presentation in the immune system and this process is therefore likely to be of 
importance in development of autoimmunity in general. There is also evidence for a 
higher risk of other autoimmune diseases in first degree relatives of MS patients 
(Broadley et al. 2000). Finally, many of the non-MHC genetic loci associated with 
MS are also associated with other autoimmune diseases (see 2.3.3). 
 
Studies in animal model 
 
According to the prevailing theory MS is mediated by T helper (Th) cells, which are 
CD4+ T cells that primarily activate other immune cells by producing various 
signaling molecules such as cytokines and chemokines. This hypothesis is largely 
based on studies in the animal model of MS, experimental autoimmune 
encephalomyelitis (EAE), which can be induced in rodents and primates by injection 
of myelin components or by adoptive transfer of activated myelin-recognizing T 
cells to an unaffected animal (Gold et al. 2006). However, while there are clear 
similarities between EAE and MS, with both demonstrating CNS inflammation and 
demyelination, it is not clear how well the pathogenesis of induced EAE 
corresponds to that of spontaneously developing and pathologically more 
heterogeneous MS (Gold et al. 2006). In addition, there is no EAE model that shows 
a similar disease course to PPMS. 
 
Activation of immune response 
 
Evidence from rats suggests that only activated T cells can cross the normally 
impermissible blood-brain barrier (BBB) and gain access to CNS (Hickey et al. 
1991). However, it is not clear how and where the activation of auto-reactive T cells 
occurs in MS patients. It has been shown in mice that T cells can be activated in 
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peripheral lymphoid organs by myelin-presenting antigen presenting cells (APC), 
specifically dendritic cells (DC), which are able to migrate out of the CNS (Karman 
et al. 2004). Another theory is that some viral or bacterial antigens with similarity to 
myelin antigens activate myelin-specific T cells (Wucherpfennig and Strominger 
1995). However, due to lack of convincing evidence of association between MS and 
any specific pathogen, this molecular mimicry theory remains controversial (Libbey 
et al. 2007). Finally, although it seems to be the general view that T cells are 
activated prior to entry into CNS, it has been shown in EAE that also naive 
lymphocytes are able to gain access to CNS if it is already inflamed (McMahon et al. 
2005). 
 
Once lymphocytes have accessed CNS, auto-reactive T cells are thought to become 
re-activated upon encountering endogenous myelin antigens presented to them by 
APCs. Re-activated T cells begin to produce chemokines and cytokines which 
activate CNS cells such as microglia and astrocytes, and promote recruitment of 
other immune cells from peripheral blood, including CD8+ T-cells, B-cells, mast 
cells, monocytes and macrophages (Sospedra and Martin 2005) (Figure 2.). Their 
potential roles in MS pathogenesis are covered in more detail in 2.1.3. These cells 
further produce various pro-inflammatory molecules, complement proteins and 
nitrogen and oxygen radicals, although the relevance of these molecules in MS 
pathogenesis is not understood in detail (Sospedra and Martin 2005). 
 
Demyelination 
 
The direct cause of demyelination in MS is still unclear. Activation of the 
complement system, which is a central mechanism in clearing pathogens, may be 
responsible for myelin destruction as suggested by presence of complement proteins 
in demyelinated MS lesions (Compston et al. 1989, Storch et al. 1998, Ingram et al. 
2009). Also nitric oxide has been shown to be toxic to myelin producing cells, 
oligodendrocytes, in vitro (Mitrovic et al. 1995). 
 
Nevertheless, it has been proposed that as myelin becomes destructed, additional 
myelin peptides become exposed and auto-reactive T cells recognizing these 
particular epitopes (i.e. parts of antigens recognized by immune cells) are activated. 
This epitope spreading phenomena, where an initial response to one epitope results 
in tissue destruction and thereby in release of new epitopes and activation of cells 
recognizing these epitopes, could be responsible for chronicity of the inflammatory 
reaction in MS (Tuohy and Kinkel 2000). 
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Figure 2. Hypothetic scenario of events leading to demyelination in MS. Based 
on text and figures in a review by Sospedra and Martin (2005). 
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2.1.3 Role of different cells in MS pathogenesis 
 
Although the critical first event in MS pathogenesis is likely to be the activation of 
auto-reactive Th cells by DCs or other APCs expressing MHC, also other cells are 
likely to play important roles in MS pathogenesis. Some of these and their functions 
are described below. The immunological cell lineages are depicted in Figure 3. 
 
 
 
 
 
 
Figure 3. Lineages of immunological cells. Dendritic cells are not shown, but can 
develop from both myeloid and lymphoid lineage progenitors. Figure from 
Wikimedia Commons by Mikael Häggström from original by A. Rad. 
 
 
Astrocytes 
 
Astrocytes are abundant CNS glial cells which provide support for neurons and 
maintain and regulate BBB. Based on studies in both MS patients and EAE, there is 
evidence for the role of astrocytes in various processes: they can attract and activate 
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T cells by producing cytokines and chemokines, aid the access of peripheral cells 
through BBB and impede remyelination, but on the other hand have also been 
suggested to limit effects of proinflammatory factors and to provide support for 
oligodendrocytes (Nair et al. 2008). They also uptake glutamate, a neurotransmitter 
which is highly toxic to oligodendrocytes in vitro (Oka et al. 1993) and can thereby 
have a protective role for oligodendrocyte survival (Corley et al. 2001). Finally, 
astrocytes can also act as APCs and present MBP peptides to T cells in rats (Fontana 
et al. 1984). There are thereby several protective and promoting mechanisms by 
which astrocytes could contribute to MS pathogenesis. 
 
B lymphocytes 
 
Plasma cells, which are differentiated B cells, are specialised in antibody production. 
In MS, B cells and plasma cells are recruited from the peripheral blood to CNS 
where plasma cells produce antibodies presumably against some components of 
myelin. The production of antibodies is evidenced by oligoclonal immunoglobulin 
bands, which are characteristically detected in CSF of MS patients by protein 
electrophoresis. However, the antigen specificity of these antibodies and their 
relevance for MS pathogenesis remain unknown. In addition to being precursors for 
plasma cells, B cells may also have other important functions in MS such as acting 
as APCs and producing proinflammatory cytokines (McLaughlin and 
Wucherpfennig 2008). Successful clinical trials with rituximab which specifically 
targets CD20, a surface molecule expressed by naive, developing and memory B 
cells but not plasma cells, also suggests a role for B cells in MS pathogenesis (Bar-
Or et al. 2008, Hauser et al. 2008). 
 
CD4+ T cells 
 
CD4+ T cells are a heterogeneous cell population including Th cells and regulatory 
T cells (Tregs). Three types of Th cells have now been characterised: Th1, Th2 and 
Th17 cells. The antigen specificity of Th cells is determined by the T cell receptor 
(TCR), which is expressed on cell surface. TCR recognizes its antigen when the 
antigen is presented in the context of Major Histocompatibility Complex Class II 
(MHCII) molecules on the surface of APCs such as DCs. Given that MHCII variants 
are a major risk factor for MS, antigen presentation and interactions between APCs 
and CD4+ T cells are likely to play an important role in MS. After antigen 
recognition, the naive T cells develop into mature Th1, Th2 or Th17 cells depending 
on cytokines present in the environment (Harrington et al. 2006). The different types 
of Th cells also have distinct cytokine expression profiles: among other cytokines 
Th1 cells are characterized by secretion of IFN-!, Th2 cells by production of IL-4 
and Th17 cells by production of cytokine IL-17A (Cherwinski et al. 1987, 
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Harrington et al. 2005, Park et al. 2005). Thereby the different Th cell types have 
different effects on other cells of the immune system. 
 
Evidence from early studies in EAE suggested that Th1 cells are responsible for 
initiating the inflammatory response, while Th2 cytokines were regarded to act as 
counter-inflammatory by antagonising Th1 cells (Olsson 1992, Gold et al. 2006). 
The importance of Th1 cells was also supported by studies in human, as Th cells 
from CSF of MS patients were shown to produce IFN-! (Benvenuto et al. 1992, 
Olsson 1992). In addition, increased Th1/Th2 balance has been associated with 
active inflammation in MS patients (Misu et al. 2001, Nakajima et al. 2004). On the 
other hand it has been shown that at least the major cytokine produced by Th1 cells, 
IFN-!, is not required for development of EAE (Ferber et al. 1996). Finally, Th2 
cells are also able to induce EAE under certain conditions (Lafaille et al. 1997).  
 
Recently the role of Th17 cells has, however, been gaining increasing attention in 
studies of MS and other autoimmune diseases. Higher numbers of IL-17 producing 
cells have been reported in blood and CSF of MS patients (Matusevicius et al. 1999) 
and in EAE it was shown that a Th17-related cytokine IL-23, rather than IL-12 
which drives Th1 differentiation, was required for development of EAE (Cua et al. 
2003, Harrington et al. 2006). Various processes have been suggested through which 
these cells could contribute to MS, including affecting BBB breakdown, activation 
and recruitment of neutrophils and stimulation of production of proinflammatory 
molecules (Segal 2010). 
 
Finally, unlike Th cells which have primarily pro-inflammatory effects, Tregs act in 
suppressing immune responses and are thereby important in controlling 
inflammation and in maintaining peripheral tolerance to auto-antigens. This has 
been demonstrated in mice, in which depletion of Tregs results in systemic 
autoimmunity (Sakaguchi 2000). Although there is no evidence for their decreased 
levels, Tregs isolated from MS patients show impaired suppressive functionality 
(Viglietta et al 2004). 
 
CD8+ T cells 
 
CD8+ T cells are a subset of T cells, also called cytotoxic T cells because of their 
capacity to induce cell death. Unlike CD4+ T cells which recognize MHCII 
molecules on the surface of APCs, CD8+ cells interact with Major 
Histocompatibility Complex Class I (MHCI) molecules which present primarily 
viral antigens. CD8+ T cells are found in MS lesions and are associated with axonal 
damage (Babbe et al. 2000). Myelin-specific CD8+ T cells are also able to induce 
CNS autoimmunity in mice and this condition was found to display MS-like features 
not observed in CD4+ cell -induced disease (Huseby et al. 2001). 
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Dendritic cells 
 
DCs are professional APCs: their main function is to present antigens bound to 
MHC molecules on their cell surface to T cells. DCs can be divided into two main 
types: myeloid dendritic cells (mDC) and plasmacytoid dendritic cells (pDC), which 
differ with respect to their antigen uptake and cytokine secretion profiles (Shortman 
and Liu 2002). The potential role of DCs in MS is supported by findings that 
peripheral DCs, specifically mDCs, accumulate in CNS in EAE, acquire myelin 
debris and present it to CD4+ T-cells in vivo (Greter et al. 2005, Bailey et al. 2007). 
Furthermore, functional abnormalities and elevated CSF levels of pDCs have been 
reported in MS patients (Pashenkov et al. 2001, Stasiolek et al. 2006). In addition, 
IFN-beta and glatiramer acetate have been found to affect DC functions from MS 
patients in vitro (Hussien et al. 2001, Stasiolek et al. 2006). 
 
Granulocytes 
 
The role of granulocytes (eosinophils, basophils, neutrophils) in MS has so far been 
scarcely studied. However, there is evidence for elevated levels of neutrophils in 
peripheral blood of PPMS patients (McKay et al. 2008) and IFN-beta has been 
shown to prevent neutrophil infiltration to CNS in rat (Veldhuis et al. 2003), 
suggesting yet another potential mechanism by which IFN-beta treatment could 
ameliorate the clinical condition in MS. In addition, depletion of peripheral blood 
granulocytes delayed and in some cases completely prevented the development of 
EAE in mice (McColl et al. 1998). 
 
Microglia and macrophages 
 
Microglia are CNS glial cells, i.e. non-neuronal cells of the nervous system, whereas 
macrophages are found in peripheral blood and in MS are found to migrate to CNS. 
Both are critical players in innate immunity and have the ability to identify foreign 
agents and debris and phagocytose them. The functions of macrophages and 
microglia in MS and EAE have been reviewed by Raivich and Banati (2004). Both 
cells can act as APCs and interact with T cells in CNS. They also produce various 
substances such as cytokines, chemokines, complement components, cell adhesion 
glycoproteins, reactive oxygen species and neurotrophins, which may have both 
protective and damaging effects on neurons and oligodendrocytes. 
 
Natural killer cells 
 
Natural killer (NK) cells play an important role in causing death of virus-infected 
cells and cancer cells by producing and releasing toxic substances. While there is 
evidence for their involvement in MS from studies in both humans and EAE, the 
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results are somewhat controversial and suggest both protective and promoting 
mechanisms (Morandi et al. 2008). Proposed MS promoting mechanisms by NK 
cells include polarization of Th1 cells through cytokine release, direct damage to 
CNS tissue, and activation of DCs. Potential protective mechanisms include release 
of cytokines which induce Th2 cells or Tregs, killing of immature DCs or killing of 
myelin-specific T cells. 
 
Oligodendrocytes 
 
Oligodendrocytes, or oligodendroglia, are myelin-forming cells of CNS. They are 
normally capable of forming new myelin sheath around demyelinated axons in a 
process called remyelination. However, defects in remyelination in MS patients have 
been shown, possibly resulting from disabled proliferation and differentiation of 
oligodendrocyte precursor cells into mature oligodendrocytes (Wolswijk 1998).  
 
 
2.2 Unravelling the genetics of complex diseases 
2.2.1 Genetics of complex traits 
 
Complex traits are phenotypes determined by multiple genetic and/or environmental 
factors and possibly also their interactions. While monogenic traits, which are 
controlled by single genes, show a Mendelian inheritance pattern within pedigrees 
(hence also called Mendelian traits), no obvious transmission pattern is seen in 
complex phenotypes. Although familial aggregation and correlation is commonly 
observed also in case of complex traits, this does not always imply that a significant 
genetic component is involved. The proportion of variation in a phenotype explained 
by genetic variation can be estimated with a parameter called heritability, h2. Broad-
sense heritability (hb2) is the ratio of total genetic variance to total phenotypic 
variance and can be estimated for example from concordance rates (r) in 
monozygotic (MZ) and dizygotic (DZ) twins according to: hb2=2(rMZ-rDZ) (Falconer 
and MacKay 1996). Narrow-sense heritability (hn2) is the proportion of phenotypic 
variance explained by additive genetic variance and hence does not take into account 
dominance and epistatic genetic effects, i.e. relationships between genetic variants 
within and between loci, respectively. Narrow-sense heritability can be estimated 
from concordances in siblings (rsib) and adoptees (rad): hn2 = rsib-rad. 
 
There are many types of genetic variants, which can potentially explain the genetic 
component of a variable trait. Microsatellites, or single sequence repeats (SSR), are 
variants consisting of a short repeat sequence of 2-4 bp, while minisatellites 
 THL  –- Research 65/2011 28 Studies on causes of  multiple sclerosis 
 
(variable number of tandem repeats, VNTR) are repeats of about 10-100 bp 
sequence (Ramel 1997). Allelic variants differ in the number of times this sequence 
is consecutively repeated in the locus. Micro- and minisatellites are generally highly 
mutable and thereby highly polymorphic. Microsatellites in particular have been 
found to cause rare disorders including Fragile X syndrome and Huntington's 
disease (Ramel 1997) and have also been useful in mapping of complex disease loci. 
It remains to be shown whether some of them also play a direct role in altering 
susceptibility to complex traits. 
 
The first drafts of the human genome sequence were published in 2001 
independently by the private company Celera Genomics (Venter et al. 2001) and the 
public-sector Human Genome Project (HGP) (Lander et al. 2001). Shortly after, 
HGP data together with data from the SNP Consortium project provided the first 
dense map of over 1.4 million SNPs (Sachidanandam et al. 2001). SNPs are allelic 
variants at a specific nucleotide position and are usually bi-allelic, showing two of 
the four bases (adenine (A), cytosine (C), guanine (G), thymine (T)). In comparison 
with micro- and minisatellites SNPs are relatively evenly distributed in the genome 
and are much more common within genes. The majority of genetically determined 
phenotypic variation is therefore likely to be explained by SNPs. 
 
With the aim of cataloging common SNP variants in different ethnic populations, 
the International HapMap Project was initiated in 2002 (International HapMap 
Consortium 2003). The data produced by this effort has also allowed identification 
of ”tagging SNPs”, i.e. SNPs which are informative in predicting alleles at nearby 
SNPs due to correlation, or linkage disequilibrium (LD), between SNPs within so 
called haploblocks. This data was soon widely applied for selecting SNPs for 
association studies. However, the HapMap project was primarily targeting common 
SNP variants with minor allele frequency (MAF) >1%. In order to identify and 
catalogue rarer SNPs, the 1000 Genomes Project was launched in early 2008 by the 
international 1000 Genomes Consortium (http://www.1000genomes.org/page.php). 
Using next-generation re-sequencing techniques, the pilot phase of this project 
identified approximately 15 million SNPs, 1 million short (1-50 bp) insertion-
deletion polymorphisms (INDEL) and 20,000 larger structural variants of >1 kb 
(including tandem repeats and tandem duplications, transposable elements, and large 
insertions and deletions) (1000 Genomes Project Consortium et al. 2010). The 
majority of all identified variants were previously undescribed; expectedly most of 
the common SNP variants were previously known, but most of the SNPs with lower 
frequencies (MAF <5%) as well as most of all INDELs and structural variants were 
novel. While the importance of rare SNPs, INDELs and structural variants in 
complex diseases remains to be studied, it seems that at least the more common and 
relatively large (>500 bp) structural variants, also called copy number variants 
(CNVs), are unlikely to play a major role in complex diseases: a recent genome-
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wide CNV association study in 16,000 cases of eight common diseases and 3,000 
controls identified only three associated CNV loci (WTCCC et al. 2010). 
Furthermore, the majority of common CNVs are well tagged by common SNPs, 
suggesting that they are unlikely to explain much of the void left by genome-wide 
SNP association studies (Conrad et al. 2010, WTCCC et al. 2010). 
 
2.2.2 Linkage studies 
 
High-resolution microsatellite maps which became available in the early 1990's 
paved the way for genome-wide linkage studies, in which microsatellite variants are 
screened for co-segregation with the phenotype in families with at least two affected 
individuals. A marker is linked to the phenotype if it is transmitted together with the 
phenotype significantly more often than would be expected if the marker and 
phenotype were inherited independently. Linkage can therefore only occur if the 
locus affecting the phenotype is located in the same chromosome with the tested 
marker, and close enough so that in most meiosis within a pedigree there is no 
recombination between the marker and the locus encoding the trait. The drawback of 
linkage studies is that the identified regions are large, possibly carrying hundreds or 
thousands of genes. 
 
While linkage studies have been extremely successful in leading to identification of 
genes underlying monogenic disorders, this has not been the case with complex 
diseases (Altmüller et al. 2001). With realistic sample sizes the power to detect 
linkage is low if the effect of the contributing locus on the phenotype is modest 
(Risch and Merikangas 1996). The fact that widely replicated linkage signals are 
virtually lacking in complex diseases therefore implies that loci with major impact 
are unlikely to significantly contribute to these conditions. 
 
2.2.3 Association studies 
 
The first comprehensive SNP maps together with developments in SNP genotyping 
techniques allowed a shift to another approach, association studies. In testing for 
association, the allele frequencies are compared between affected individuals and 
healthy controls. Alternatively, family based association tests can be used to test 
whether an allele is transmitted to an affected offspring more often than would be 
expected under random Mendelian segregation (Figure 4). 
 
Early association studies focused on regions with some evidence of linkage or on 
candidate genes selected on functional basis and were generally conducted in rather 
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small samples. However, only few of the associations in these early studies were 
replicated by others. This irreproducibility could be explained by a variety of factors 
including initial false positives due to chance or population stratification, variable 
LD structures between populations, population specific gene-gene and gene-
environment interactions and false negative replication efforts (Hirschhorn et al. 
2002), the first of which is probably the most likely explanation in most cases in the 
light of our current knowledge. 
 
For the last few years it has, however, been possible to conduct genome-wide 
association studies (GWASs), where 300,000-1,000,000 SNPs are simultaneously 
genotyped and tested for association. While GWASs have been successful in 
revealing novel risk variants in a variety of complex disorders, the risk effects of 
these common variants have been found to be low (odds ratio (OR) <1.5) and 
additional genetic risk factors therefore remain to be discovered (McCarthy and 
Hirschhorn 2008, Altshuler et al. 2008). To what extent rarer SNP variants 
contribute to susceptibility to complex traits will be the focus of research in the next 
years. Data from the 1000 Genomes Project can be used to impute rare variants in 
existing GWAS datasets and as the costs of sequencing are rapidly decreasing, 
whole genome sequencing of large samples will eventually become feasible. 
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Figure 4. Principle of case-control and family based association studies. In a 
case-control setting, a two-tailed chi-square test is conducted in order to test the 
hypotheses that allele counts are different in the two groups, against the null 
hypotheses that there is no difference. One commonly used family based test is the 
transmission disequilibrium test (TDT), which counts the number of times alleles are 
transmitted to the affected offspring from heterozygous parents. Under the null 
hypotheses of no association, alleles are expected to be transmitted randomly 
according to Mendelian segregation. In this example 13 of 16 heterozygous parents 
transmit allele “A” to their offspring and 3 transmit allele “a”. A chi-square test is 
conducted to assess, whether these observed counts differ significantly from 
expected. 
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2.2.4 Expression studies 
 
Until recently, there were two main approaches for genome-wide analysis of gene 
expression: microarrays and Serial Analysis of Gene Expression (SAGE) 
(Velculescu et al. 1995). Shortly, SAGE is based on sequencing of short tags of 
complementary DNA (cDNA), which can then be identified by sequence searches 
against public databases and quantified directly based on sequence counts. The 
benefit of the technique is that basically any transcript present in the sample can be 
detected. Microarrays on the other hand are limited to detecting only transcripts for 
which there are probes present on the microarray, but have become the method of 
choice for genome-wide expression profiling. Latest microarray platforms cover all 
known human genes and also contain probes for detecting alternative isoforms, i.e. 
transcripts which are encoded from the same gene but contain a different set of 
exons or differ at their 5' or 3' untranslated regions (UTR). There are several 
different types of microarrays. Affymetrix microarrays, also called GeneChip arrays 
(Affymetrix, CA, USA) differ from other types of microarrays, because the short 
oligonucleotide probes are extended directly on the surface of silicon chips by 
photolithography. In other types of microarrays, the probes (either cDNA from a 
library or synthesized oligonucleotides) are attached on the surface of a solid support 
rather than being synthesized in situ. cDNA microarrays are usually hybridised to 
cDNA from two different samples (one of the samples can be a reference sample 
used in all arrays to be compared) labeled with different fluorescent dyes (usually 
Cy3 (green) and Cy5 (red)). The two labeled samples are mixed together and 
hybridised on the same array. Spot intensity is determined for the two wavelengths 
(detecting e.g. Cy3 and Cy5) and their ratio represents the difference in the amount 
of transcript in the two samples. In contrast, Affymetrix chips are hybridised with 
only one sample (see Figure 5 for Affymetrix workflow). After hybridisation with a 
labeled sample arrays are washed to remove unhybridised sample and scanned to 
measure the fluorescence signals. Because one-color experiments do not allow 
incorporation of a reference sample on the same array, normalisation and data 
analyses differ from that of two-color experiments. Raw data from most recently 
published microarray experiments is available in public data repositories such as the 
Gene Expression Omnibus (GEO) by National Center for Biotechnology 
Information (NCBI). 
 
Microarrays have been widely used for comparing expression profiles between 
patients and healthy controls in order to identify genes, which show changes in 
transcript levels in affected individuals. However, genes with altered expression are 
not necessarily involved in causing the disease, since many genes may also show 
altered expression after disease onset due to activation of protective mechanisms or 
secondary pathogenic processes, for example. In addition to the potential effects of 
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the disease itself, measured gene expression levels can be influenced by various 
non-biological and biological factors including genetic variants (some of which may 
be disease risk variants) (Figure 6). Genetic loci which correlate with gene 
expression are called expression quantitative trait loci (eQTL). Studies correlating 
genome-wide SNP data with genome-wide expression data have now identified 
thousands of eQTLs and their target genes (Dimas et al. 2009, Dixon et al. 2007, 
Moffatt et al. 2007, Myers et al. 2007, Schadt et al. 2008, Stranger et al. 2007, 
Veyrieras et al. 2008, Zeller et al. 2010). eQTLs can be located close to the gene(s) 
they regulate in which case they are said to be cis-acting, or further away or in a 
different chromosome, in which case they are trans-acting. Although in most cases 
the mechanisms by which eQTLs exert their effects on gene expression are still 
unknown, cis-acting SNPs may for example have an impact on efficiency of 
transcription factor binding, while trans-acting SNPs may alter the expression or 
structure of nearby transcription factors or microRNAs (miRNA), i.e. short RNA 
molecules which bind to their target mRNAs and regulate their degradation and 
translation efficiency. This in turn has consequences on the expression of their target 
genes in other loci (in trans). Many eQTLs may be tissue- or cell type-specific 
(Dimas et al. 2009) and studies correlating disease risk variants with gene 
expression should therefore ideally focus on a tissue or cell population, which is 
known to be relevant for the disease. 
 
Decreased costs of next-generation sequencing techniques have recently made it 
possible to sequence the transcriptome, i.e. the entire set of ribonucleic acid (RNA) 
molecules in a given sample. This technique called RNA-sequencing (RNA-Seq) 
enables not only quantitative analysis but also precise identification of 
transcriptional isoforms (Nagalakshmi et al. 2008). RNA-Seq is, however, still 
costly in comparison with microarrays. 
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Figure 5. Affymetrix® microarray experiment workflow. Figure is based on text 
and figures in GeneChip® Expression Analysis Technical Manual (Affymetrix®) 
(www.affymetrix.com). In the first step the first strand of cDNA is created by using 
T7-Oligo(dT) promoter primer, which recognizes mRNA poly(A) and has a binding 
sequence for T7 RNA polymerase. Second cDNA strand is then synthesised to serve 
as template for complementary RNA (cRNA) strand amplification. In addition to 
normal ribonucleotides, biotin-labeled pseudouridine nucleotides are also added into 
the reaction and become incorporated in the cRNA at random uridine positions. 
After clean-up and fragmentation of cRNA molecules into 25-200 bp fragments, the 
fragments are hybridized on the chip containing complementary oligonucleotide 
probes. Streptavidin-phycoerythrin is then added into the reaction: streptavidin binds 
strongly with biotin present on the cRNA fragments while phycoerythrin acts as a 
fluorescence marker. Fluorescence signal is further amplified by adding biotinylated 
anti-streptavidin. Strength of the fluorescence signal reflects the amount of cRNA 
bound to each of the spots containing millions of copies of a specific probe sequence. 
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Figure 6. Factors affecting gene expression profiles in microarray experiments. 
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2.3 Epidemiology and genetics of MS 
2.3.1 Epidemiological studies and role of environment in MS 
 
The prevalence of MS is typically high (100-200/105) in Northern Caucasian 
populations (Northern Europe and North America), but also for example in 
Sardinians, Sicilians, Indian Parsis and Palestinians (Figure 7, Pugliatti et al. 2002). 
Low prevalences are found in Southern Europe, Southern America and Australia and 
New Zealand and the disease is rarely encountered in black African, Asian and 
many indigenous populations such as Samis and Maoris (Pugliatti et al. 2002). 
These differences between populations are likely to be explained by both genetic 
and environmental factors as well as their interactions. Increased prevalence and 
incidence of MS during the past decades, particularly in females, seem to be rather 
universal phenomena, and suggest an increasing exposure to some environmental or 
lifestyle-related risk factors (Koch-Henriksen and Sørensen 2010). 
 
Biological relatives of MS patients have a significantly increased risk for developing 
MS (Table 2). The role of genetic factors in explaining familial aggregation has been 
shown in twin and adoption studies: risk of developing MS is higher in MZ twins of 
affected individuals than in their DZ twins or siblings (Willer et al. 2003), while the 
risk is not increased in non-biological family members of adopted MS patients 
(Ebers et al. 1995). A shared family environment therefore does not seem to 
predispose to MS, suggesting that the environmental influences act on a population 
level. 
 
The role of various environmental factors in MS has been investigated. Pathogens 
have been studied quite extensively, but no undisputable evidence has been obtained 
for their involvement. One of the most studied viruses is the Epstein-Barr virus 
(EBV), which is a ubiquitous herpes group virus with cross-reactivity with MBP 
(Lang et al. 2002). Serafini et al. (2007) found EBV infected B cells in 21 of 22 
post-mortem MS brain samples, but not in 11 non-MS control samples, most of 
which were obtained from sufferers of other inflammatory neurological diseases. 
However, two more recent studies failed to replicate these findings (Willis et al. 
2009, Fatima et al. 2011) and the role of EBV in MS remains elusive. 
 
Based on the observed higher prevalence of MS in Northern countries, association 
between MS and sunlight exposure and D vitamin levels has also been hypothesized 
(Ascherio et al. 2010). While there is some evidence for a protective effect of D 
vitamin, the precise mechanisms and role of gene-environment interactions remain 
to be further investigated. 
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Given that MS is more common in females than in males, sex hormones have also 
been suggested to play a role in MS (Shuster 2008). Relating to this hypothesis, 
earlier age at menarche has been shown to increase the risk for MS (Ramagopalan et 
al. 2008). 
 
Lifestyle factors commonly suggested to increase the risk for MS include smoking 
(Hawkes 2007, Sundström et al. 2008), possibly in interaction with MS risk variants 
at Human Leukocyte Antigen (HLA) genes (Hedström et al. 2011), and diet (Lauer 
1994).  
 
 
 
 
Table 2. Prevalence of MS in relatives of MS probands (Ebers 2008). 
 
Relationship to MS patient Prevalence (%) Identity by descent (%) 
Adoptive sibling 0.1 0 
First cousin 0.7 12.5 (on average) 
Paternal half sibling 1.3 25 (on average) 
Half sibling reared apart 2.1 25 (on average) 
Maternal half sibling 2.4 25 (on average) 
Full sibling 3.5 50 (on average) 
Sibling in consanguineous 
mating 
8 50 (on average) 
Offspring of conjugal mating 20 50 
Monozygotic twin 27 100 
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Figure 7. Prevalence of MS in European populations. Based on data from 1990-
2010 (Binzer et al. 1994, Cavalletti et al. 1994, Fernández et al. 1994, van 
Ooteghem et al. 1994, Rice-Oxley et al. 1995, Sharpe et al. 1995, Robertson et al. 
1996, Dean et al. 1997, Uria et al. 1997, Benito-León et al. 1998, Bencsik et al. 
1998, Casetta et al. 1998, Ford et al. 1998, Grant et al. 1998, McDonnell and 
Hawkins 1998, Pina et al. 1998, Rothwell and Charlton 1998, Forbes et al. 1999, 
Gross-Paju et al. 1999, Milanov et al. 1999, Potemkowski 1999, Tola et al. 1999, 
Grønlie et al. 2000, Hein and Hopfenmüller 2000, Moreau et al. 2000, Bencsik et al. 
2001, Casquero et al. 2001, Grimaldi et al. 2001, Kurtzke and Heltberg 2001, 
Sumelahti et al. 2001, Baumhackl et al. 2002, Benedikz et al. 2002, Dean et al. 2002, 
Sundström et al. 2003, Dahl et al. 2004, Fox et al. 2004, McGuigan et al. 2004, 
Murray et al. 2004, Ragonese et al. 2004, Sarasoja et al. 2004, Tienari et al. 2004, 
Nicoletti et al. 2005a, Nicoletti et al. 2005b, Pugliatti et al. 2005, Solaro et al. 2005, 
De Sá et al. 2006, Grytten et al. 2006, Peterlin et al. 2006, Ares et al. 2007, 
Debouverie et al. 2007, Granieri et al. 2007, Grimaldi et al. 2007, Granieri et al. 
2008, Gray et al. 2008, Iuliano and Napoletano 2008, Papathanasopoulos et al. 2008, 
Smestad et al. 2008, Boström et al. 2009, Bentzen et al. 2010). 
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2.3.2 Linkage studies 
 
The first three genome-wide MS linkage scans, conducted in UK, US and Canada, 
were published back to back in 1996 (Ebers et al. 1996, Haines et al. 1996, Sawcer 
et al. 1996). These were followed by genome-wide scans in Finland (Kuokkanen et 
al. 1997), Italy (Broadley et al. 2001), Sardinia (Coraddu et al. 2001), Scandinavia 
(Akesson et al. 2002), Australia (Ban et al. 2002) and Turkey (Eraksoy et al. 2003). 
None of these studies identified any loci with a genome-wide significant logarithm 
of odds (LOD) score >3, although several loci with suggestive evidence for linkage 
were identified. A meta-analysis of all nine linkage scans containing 719 families 
and on average 359 microsatellite markers per family did not identify any loci with 
LOD >3 apart from the MHC, although loci on 17q21 and 22q13 were suggestively 
linked (GAMES 2003). 
 
Later, extended studies were published by the groups in UK, US-France and Canada 
(Hensiek et al. 2003, Dyment et al. 2004b, Kenealy et al. 2004). Significant 
evidence for linkage at the MHC locus was found in Canadian and US-French 
studies. Finally, a large linkage study in 730 pedigrees with over 4500 SNPs 
conducted by the IMSGC failed to identify any non-MHC regions with significant 
linkage (Sawcer et al. 2005). Based on these studies it was concluded that any 
common non-MHC alleles are likely to increase MS risk by a factor of <2.0 (Sawcer 
2008). However, the poor overlap across linkage studies and the failure of larger 
scans to detect significant non-MHC loci may also to some extent reflect locus 
heterogeneity in MS between and within populations. 
 
In Finnish MS pedigrees linkage studies identified four candidate regions with 
evidence of linkage: the MHC locus on 6p (LODmax=6.4, Tienari et al. 1993), 5p12-
p14 (LODmax=3.4, Kuokkanen et al. 1996), 17q22-q24 (LODmax score=2.8, 
Kuokkanen et al. 1997) and the myelin basic protein locus on 18q23 (LODmax=3.3, 
Tienari et al. 1992). In addition, 19q13.1 showed weak evidence for linkage in 
HLA-DR15 negative families (LODmax=1.8, Reunanen et al. 2002). The linked 
region on chromosome 17 was later narrowed down by fine mapping to a 2.5 Mb 
segment (LODmax=2.9, Saarela et al. 2002) and the region on chromosome 5 to 5.3 
Mb (LODmax=3.5, Riise Stensland et al. 2005). Loci on 5p and 17q have emerged 
also in other studies (Dyment et al. 2004b; Eraksoy et al. 2003, Hensiek et al. 2003, 
Sawcer et al. 2005) with LOD scores 1.1-2.45 and are syntenic with susceptibility 
loci in EAE mouse and rat (Jagodic et al. 2001; Sundvall et al. 1995). However, all 
linkage regions are still wide and contain numerous candidate genes, some of which 
have been further investigated in association studies (see 2.3.3). 
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2.3.3 Association studies 
 
Prior to platforms for genome-wide SNP genotyping, association studies needed to 
be targeted on specific loci or genes, usually selected on the basis of evidence of 
linkage or a functional hypothesis. Given that any gene with a neurological or 
immunological function would make a valid candidate for an MS susceptibility gene, 
it is not surprising that most association studies have failed to find association, while 
the initial positive findings have rarely been replicated, indicating high false positive 
rates in these early candidate gene studies. On the other hand, since the first studies 
were conducted in small samples, some true signals may have been missed as well. 
The only solid finding for a long time was the MHC region, which is indisputably 
the strongest genetic risk factor for MS. However, as a result of recent GWASs there 
are currently close to 50 non-MHC loci, which are associated with MS with 
genome-wide significance (GWS) (P-value " 5x10-08). Most of these are located at 
or near genes with immunological functions. 
 
Major Histocompatibility Complex (MHC) 
 
First associations of HLA protein variants, which are encoded by HLA-genes within 
the MHC region, with MS were described nearly four decades ago (Naito et al. 1972; 
Jersild et al. 1972; Bertrams et al. 1972). The since identified DNA risk haplotype 
HLA-DRB1*1501-DQA1*0102-DQB1*0602 has been widely replicated (Schmidt 
et al. 2007) and is estimated to explain 17%-62% of MS heritability (Haines et al. 
1996). However, it still remains unclear which of the genes is the main determinant 
of increased risk for MS, and whether there are several susceptibility genes within 
the MHCII region. The HLA-genes within MHCII encode molecules expressed on 
the surface of APCs and present antigens to CD4+ cells, but the mechanisms by 
which the MS associated variants result in increased susceptibility are currently 
unknown. In addition to MHCII, there is also evidence for independent risk factors 
in the MHCI region (Harbo et al. 2004, Yeo et al. 2007, De Jager et al. 2009, 
IMSGC and WTCCC2 2011). 
 
Non-MHC loci 
 
As of April 2011 seventeen non-MHC loci had been reported to be associated with 
MS with GWS (Table 3). In addition, a study in nearly 10,000 MS patients and more 
than 17,000 controls conducted by the IMSGC and the Wellcome Trust Case 
Control Consortium 2 (WTCCC2) had been completed at the time of writing this 
thesis and had identified 29 novel risk loci (IMSGC and WTCCC2 2011) (Table 4). 
However, the reported ORs for all confirmed risk variants are low (1.1-1.4) and even 
together with the MHC region, much if not most of the genetic variants contributing 
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to MS heritability still remain to be identified. Further finemapping and functional 
studies are also required in order to pinpoint the functionally relevant variants and 
genes in the currently known loci, many of which extend over several hundred kb 
and contain several genes. Many candidate genes in these loci have immunological 
functions (CD58, CD6, CD86, CLEC16A, CLECL1, GPR65, EOMES, IL12A, IL12B, 
IL2RA, IL22RA2, IL7R, IRF8, MALT1, MERTK, SP140, STAT3, TAGAP, 
TNFRSF1A, TNFSF14, TYK2), although interestingly some genes relevant for 
neurological functions have also emerged (AHI1, GALC, KIF21B). Strikingly many 
of the established loci overlap with those identified in other autoimmune diseases 
(Table 5). These findings point towards partially shared causative mechanisms even 
in diseases with very different manifestations such as MS and celiac disease (CD). 
 
The mechanisms through which MS variants exert their effects on disease 
susceptibility are currently poorly understood, but it is likely that many common risk 
variants modulate gene expression. At least 30% of the GWS MS risk variants have 
an effect on gene expression of a nearby gene (Table 6). However, it is likely that 
more such effects would be identified if larger studies and studies in different 
immune cell populations were conducted. Furthermore, only one of the published 
eQTL studies had sufficient power to test for trans-regulatory effects (Zeller et al. 
2010), which may be important in regulating immunological pathways relevant in 
autoimmune diseases (Heinig et al. 2010). 
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Table 3. Non-MHC risk loci associated with MS with GWS as of April 2011.  
 
SNP Nearest 
Gene 
Description N(Cases);N(contr
ols) in original 
study 
Reference 
rs9657904 CBLB Cas-Br-M (murine) ecotropic 
retroviral transforming 
sequence b 
1775; 2005 Sanna et al. 
2010 
rs2300747 CD58 CD58 molecule 4838; 9336  De Jager et al. 
2009 
rs17824933 CD6 CD6 molecule 4838; 9336 De Jager et al. 
2009 
rs12708716 CLEC16A C-type lectin domain family 
16, member A 
5737; 10296 IMSGC 2009 
rs17445836 IRF8 interferon regulatory factor 8 4838; 9336 De Jager et al. 
2009 
rs4680534 IL12A interleukin 12A 10709; 14997 IMSGC 2010a 
rs12722489 IL2RA interleukin 2 receptor, alpha 2322; 5418 (+ 
1540 trios) 
IMSGC et al. 
2007 
rs6897932 IL7R interleukin 7 receptor 11019; 13616 IMSGC 2008 
rs10492972* KIF1B kinesin family member 1B 2679; 3125 Aulchenko et 
al. 2008 
rs12122721 KIF21B kinesin family member 21B 3507; 3395 IMSGC 2010b 
rs703842 METTL1 methyltransferase like 1; 
cytochrome P450, family 27, 
subfamily B, polypeptide 1 
3874; 5723 ANZgene 2009 
rs1790100 MPHOSPH9 M-phase phosphoprotein 
9/cyclin-dependent kinase 2 
associated protein 1 
10709; 14997 IMSGC 2010a 
rs2760524 RGS1 regulator of G-protein 
signaling 1 
10709; 14997 IMSGC 2010a 
rs744166 STAT3 signal transducer and activator 
of transcription 3 
3859; 9110 Jakkula et al. 
2010 
rs1132200 TMEM39A transmembrane protein 39A 3507; 3395 IMSGC 2010b 
rs1800693 TNFRSF1A tumor necrosis factor receptor 
superfamily, member 1A 
4838; 9336 De Jager et al. 
2009 
rs34536443 TYK2 tyrosine kinase 2 10642; 10620 
(+2110 trios) 
Mero et al. 
2010 
 
*This association was not replicated in a larger sample of 8391 cases, 8052 controls and 2137 trio 
families and is likely to have been false positive (IMSGC et al. 2010) 
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Table 4. Novel MS risk loci identified with GWS in the IMSGC and WTCCC2 
GWAS. 
 
SNP Nearest 
Gene 
Description 
rs11154801 AHI1 Abelson helper integration site 1 
rs12212193 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 
rs2300603 BATF basic leucine zipper transcription factor, ATF-like 
rs9282641 CD86 CD86 molecule 
rs10466829 CLECL1 C-type lectin-like 1 
rs669607 CMC1 COX assembly mitochondrial protein homolog (S. cerevisiae) 
rs2248359 CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 
rs2303759 DKKL1 dickkopf-like 1 
rs11129295 EOMES eomesodermin 
rs2119704 GPR65 G protein-coupled receptor 65 
rs7923837 HHEX hematopoietically expressed homeobox 
rs2546890 IL12B 
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40) 
rs17066096 IL22RA2 interleukin 22 receptor, alpha 2 
rs7238078 MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1 
rs2283792 MAPK1 mitogen-activated protein kinase 1 
rs17174870 MERTK c-mer proto-oncogene tyrosine kinase 
rs874628 MPV17L2 MPV17 mitochondrial membrane protein-like 2 
rs4410871 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
rs2019960 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
rs140522 ODF3B outer dense fiber of sperm tails 3B 
rs11581062 SLC30A7 solute carrier family 30 (zinc transporter), member 7 
rs10201872 SP140 SP140 nuclear body protein 
rs12466022 ZFP36L2 zinc finger protein 36, C3H type-like 2 
rs7595037 PLEK pleckstrin 
rs802734 PTPRK protein tyrosine phosphatase, receptor type, K 
rs1738074 TAGAP T-cell activation RhoGTPase activating protein 
rs1077667 TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 
rs4902647 ZFP36L1 zinc finger protein 36, C3H type-like 1 
rs354033 ZNF746 zinc finger protein 746 
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Table 5. GWS MS risk loci identified in other autoimmune diseases with GWS. MS 
risk loci were listed in Tables 3 and 4. NHGRI Catalog of Published Genome-Wide 
Association Studies track in the UCSC Genome Browser (April 2011) was applied to 
identify SNPs associated with other autoimmune diseases and the loci were considered 
to overlap with MS risk loci if the SNPs were located within 500kb. AA= Alopecia 
areata, CD=celiac disease, ChD=Crohn’s disease, PS=psoriasis, PSA=psoriatic arthritis, 
RA=rheumatoid arthritis, SLE=systemic lupus erythematosus, T1D=type 1 diabetes, 
UC=ulcerative colitis. 
 
Gene nearest to the MS 
associated SNP 
Associated SNP in other disease(s) (r2 with 
MS SNP based on 1000 Genomes data) 
Disease(s) 
rs10806425 (0.48) CD (Dubois et al. 2010) BACH2 
rs11755527 (0.26) T1D (Barrett et al. 2009, Cooper et 
al. 2008) 
rs12708716 (0.02) T1D (Barrett et al. 2009, Cooper et 
al. 2008, Todd et al. 2007) 
rs12928822 (0.02) CD (Dubois et al. 2010) 
CLEC16A 
rs2903692 (0.96) T1D (Hakonarson et al. 2007) 
rs3764021 (0.87) T1D (WTCCC 2007) CLECL1 
rs4763879 (0.47) T1D (Barrett et al. 2009) 
IL12A rs17810546 (0.05) CD (Dubois et al. 2010, Hunt et al. 
2008) 
rs10045431 (0.06) ChD (Barrett et al. 2008) 
rs12188300 (0.01) PSA (Hüffmeier et al. 2010) 
rs2082412 (0.31) PS (Nair et al. 2009) 
rs2546890 (0.46) PS (Ellinghaus et al. 2010) 
IL12B 
rs3213094 (0.31) PS (Zhang et al. 2009) 
rs12251307 (0.02) T1D (Barrett et al. 2009) 
rs3118470 (0.1) AA (Petukhova et al. 2010) 
rs706778 (0.12) RA (Stahl et al. 2010) 
rs706779 (0.16) Vitiligo (Jin et al. 2010) 
IL2RA 
rs947474 (0.02) T1D (Cooper et al. 2008) 
rs11584383 (0.96) ChD (Barrett et al. 2008) KIF21B 
rs296547 (0.77) CD (Dubois et al. 2010) 
MAPK1 rs131654 (0.05) SLE (Han et al. 2009) 
MYC rs9792269 (0.02 with rs4410871, 0.05 with 
rs2019960) 
CD (Dubois et al. 2010) 
PLEK rs17035378 (0.37) CD (Dubois et al. 2010) 
PTPRK rs802734 (0.36) CD (Dubois et al. 2010) 
RGS1 rs2816316 (0.94) CD (Dubois et al. 2010, Hunt et al. 
2008) 
STAT3 rs744166 (same SNP) ChD (Barrett et al. 2008) 
TAGAP rs1738074 (0.54) CD (Dubois et al. 2010) 
TYK2 rs2304256 (information not available) T1D (Wallace et al. 2009) 
ZFP36L1 rs1465788 (0.31) T1D (Barrett et al. 2009) 
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Table 6. GWS MS risk variants correlating with gene expression. The MS SNPs 
(or their best Affy 6.0 proxy) were searched in the monocyte eQTL database using 
their threshold of GWS. In addition the mRNA by SNP Browser (Dixon et al. 2007, 
Moffatt et al. 2007, database available at 
http://www.sph.umich.edu/csg/liang/asthma/) was searched for effects with LOD >3, 
again using the best proxy SNP (r2 >0.8) if the associated SNP was not available. All 
variants are cis-acting unless specified as trans. 
 
 
SNP Target gene Tissue/cell type (reference) 
SP110 LCL (mRNA by SNP Browser) rs10201872 
SP140 LCL (mRNA by SNP Browser) 
CLECL1 LCL, monocytes (mRNA by SNP Browser, Zeller et al. 2010) 
IGFL3 (trans) Monocytes (Zeller et al. 2010) 
rs10466829 
KLRB1 LCL (mRNA by SNP Browser) 
rs1077667 TNFSF14 LCL (mRNA by SNP Browser) 
rs11154801 AHI1 LCL, monocytes (mRNA by SNP Browser, Zeller et al. 2010) 
rs12708716 DEXI LCL, monocytes (mRNA by SNP Browser, Zeller et al. 2010) 
CPT1B Monocytes (Zeller et al. 2010) 
ECGF1 Monocytes (Zeller et al. 2010) 
rs140522 
KREMEN2 (trans) Monocytes (Zeller et al. 2010) 
rs17174870 MERTK Monocytes (Zeller et al. 2010) 
rs17824933 CD6 Monocytes (Zeller et al. 2010) 
MPOSHPH9 Monocytes (Zeller et al. 2010) 
OGFOD2 LCL (mRNA by SNP Browser) 
rs1790100 
SBNO1 LCL (mRNA by SNP Browser) 
rs2300747 CD58 LCL (mRNA by SNP Browser) 
rs2760524 RGS1 Monocytes (Zeller et al. 2010) 
rs4902647 ZFP36L1 LCL (mRNA by SNP Browser) 
FAM119B LCL, monocytes (mRNA by SNP Browser, Zeller et al. 2010) 
TSFM LCL, monocytes (mRNA by SNP Browser, Zeller et al. 2010) 
TSPAN31 Monocytes (Zeller et al. 2010) 
rs703842 
XRCC6BP1 Monocytes (Zeller et al. 2010) 
rs874628 CHRM4 (trans) Monocytes (Zeller et al. 2010) 
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Association studies in the Finnish population 
 
As a result of detailed screening of the candidate region 17q22-24 suggested by 
linkage studies, Saarela et al. (2006) identified the first non-MHC MS associated 
gene in the Finnish population, PRKCA, in 151 families (OR=1.34, 95% CI=1.07-
1.68). In addition, they measured PRKCA transcript levels in CD4+ T cells and in 
non-CD4+T cell PBMCs (containing all PBMCs except CD4+ T cells, i.e. CD8+ T 
cells, B cells, NK cells, monocytes, macrophages and DCs) previously collected 
from MS patients and their family members. They detected a 2-fold decrease in 
PRKCA transcript levels in non-CD4+ T cell PBMCs in carriers of two copies of the 
associated two-SNP haplotype (n=9) versus carriers of one copy (n=7), but did not 
see any significant difference in CD4+ PBMCs. Association was also demonstrated 
in 554 Canadian families in the same study, although the strongest association was 
found with a different haplotype (OR=1.64, 95% CI=1.39-1.94). In addition, 
association at PRKCA has been detected in 184 cases and 340 controls from UK (P-
value=0.002) (Barton et al. 2004). 
 
The first Finnish GWAS, conducted in 68 distantly related patients and 136 controls 
from a Southern Ostrobothnian subisolate with high MS prevalence, revealed 
associations in STAT3 and in a region on chromosome 16 in addition to HLA-DRB1 
(Jakkula et al. 2010). Association in STAT3 was replicated with GWS in 3859 cases 
and 9110 controls from more heterogeneous populations in the same study. 
Furthermore, the same variant is associated with Crohn's disease (Barrett et al. 2008). 
STAT3 is involved in various immunological signaling pathways. Interestingly, EAE 
does not develop in mice with a targeted STAT3 deletion in CD4+ T cells (Liu et al. 
2008). The associated region on chromosome 16 does not harbour any known genes, 
the nearest gene being located 1.4 Mb away, but shows a high level of evolutionary 
conservation. 
 
The GWAS data was also applied to investigate haplotype sharing at one of the most 
consistent linkage regions, 5p. This resulted in identification of a rare risk haplotype 
extending over the complement component 7 gene C7 and a gene with unknown 
function, FLJ40243 (P-value=0.0001), 5.1 Mb centromeric of IL7R (Kallio et al. 
2009). Association was replicated in samples from the same subisolate and 
suggestive evidence was detected also in more heterogeneous Northern European 
populations. The risk allele was also found to correlate with higher total complement 
activity. This finding gives support for the role of innate immunity and complement 
system in MS pathogenesis, although the role of FLJ40243 as the causative gene 
cannot be excluded at this stage. 
 
While associations at PRKCA and C7 have not been confirmed, of the currently 
known GWS MS loci IL7R and STAT3 map to the originally identified wider linkage 
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regions on chromosomes 5 and 17, respectively, and may explain some of the 
linkage signal. Of the candidate genes on the linked 19q13 region, Sulonen et al. 
(2009) tested the association of TYROBP with MS in Finnish samples based on the 
fact that loss-of-function mutations in this gene are found in a rare disease affecting 
bone and brain white matter called polycystic lipomembranous osteodysplasia with 
sclerosing leucoencephalopathy (PLOSL) (Paloneva et al. 2000). However, common 
genetic variants in this gene were found to be unlikely to play a role in MS. 
 
2.3.4 Expression studies 
 
Several microarray studies have been conducted on samples from MS patients, both 
using CNS biopsies and peripheral blood cells as the source of RNA. As with most 
microarray experiments direct comparison of these experiments is difficult. Studies 
conducted in samples from peripheral blood cells from human MS patients and 
healthy controls and including at least 10 samples in both groups are described 
below. 
 
Using Affymetrix GeneChip U95Av2, Achiron et al. (2004) studied expression of 
genes in PBMCs from 26 MS patients and 18 healthy controls. They identified a 
statistically significant transcriptional MS-signature of 1109 genes, which was not 
dependent on disease activity or treatment. These contained genes involved in T-cell 
activation and expansion, inflammation, and apoptosis. In addition, a signature of 
721 genes differed between MS patients in relapse versus those in remission. These 
genes included genes involved in cellular recruitment, epitope spreading and escape 
from regulatory immune surveillance. 
 
Arthur et al. (2008) compared whole blood expression profiles of 10 RR-MS 
patients in relapse and remission with healthy controls. Of 9381 cDNAs present on 
the array, 989 genes were significantly upregulated in relapse, including ALOX5, 
and 536 were significantly downregulated. In remission, 655 genes including 
ALOX5 were upregulated and 662 downregulated. ALOX5, encoding for 
arachidonate 5-lipoxygenase, was considered of particular interest, since it had been 
identified also in previous studies (Whitney et al. 2001, Booth et al. 2005). Over-
represented pathways among the genes upregulated during relapse were mostly 
related to apoptosis and inflammation, and genes upregulated in remission were 
found to be related to protein localization, for example. 
 
Using a cDNA microarray with 6500 (Set 1) or 7500 (Set 2) cDNA clones, 
Bomprezzi et al. (2003) conducted an experiment with fresh PBMCs from 14 MS 
patients and 7 controls and frozen blood samples from 3 patients and 2 controls (Set 
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1) in addition to another 10 frozen patient and 10 frozen control samples (Set 2). 
They reported 303 differentially expressed genes between MS patients and healthy 
controls, including IL7R. In general, several genes mapping to 6p21 (harboring the 
HLA genes, histone cluster and heatshock protein 70) were found to be differentially 
expressed. 
 
Brynedal et al. (2010) studied expression profiles in PBMCs and CSF from 26 MS 
patients and 18 controls using Affymetrix Human Genome U133 Plus 2.0 array 
covering over 47,000 transcripts. Surprisingly, no differentially expressed genes 
were identified in PBMCs, while 939 probesets were differentially expressed in CSF. 
However, patients in relapse showed differential expression in 266 probesets in 
comparison with those in remission in PBMCs. Based on these observations the 
authors conclude that MS is a CNS disease, but that events outside the CNS are 
important in triggering the relapse. 
 
The largest study so far was conducted by Gandhi et al. (2010) in whole blood 
samples from 99 untreated patients and 45 matched healthy controls. Study was 
conducted using human HT-12 expression beadchip (Illumina, Inc., CA, USA), 
which profiles 48,804 transcripts. Genome-wide SNP data was also available for 
115 of the samples from GWAS conducted by ANZgene (2009). They found a 
strong upregulation of T cell-related genes in MS, in addition to genes involved in 
translational regulation, oxidative phosphorylation, immune synapse and antigen 
presentation pathways. They also identified a significant association between CD40 
expression and CD40 MS risk haplotype, which had been identified in the 
ANZGene GWAS. There was also a strong correlation between the MS risk allele at 
12q13-14, another locus identified in the same GWAS, and expression of FAM119B, 
which is one of 13 leukocyte expressed genes in the 12q13-14 candidate region. 
 
Mandel et al. (2004) studied expression in 13 RR-MS patients, 8 SLE patients and 
10 healthy controls using Affymetrix Genechip array U95Av2. 541 genes showed 
differential expression in both MS and SLE patients compared to healthy controls 
including genes involved in apoptosis, cell cycle, inflammation and matrix 
metalloproteinase pathways. In addition, 1031 genes were specifically differentially 
expressed in MS. Genes with increased expression in MS included several genes 
encoding adhesion molecules, whereas heat shock protein genes showed decreased 
expression in MS. 
 
Ramanathan et al. (2001) compared gene expression in >4000 genes in monocyte-
depleted PBMCs from 15 RR-MS patients and 15 age- and sex matched controls and 
identified 34 genes with significantly differential expression. Expression levels of 25 
genes were increased and 9 decreased in MS. One of the upregulated genes was 
IL7R.  
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Satoh et al. (2005, 2006) conducted microarray experiments in T-cells and non-T-
cells comparing gene expression in 72 MS patients with 22 healthy unrelated 
controls. However, the used cDNA array contained only 1258 genes, thereby with a 
relatively modest coverage of the transcriptome. In T cells they identified 286 genes 
with differential expression between patients and controls, and further showed that 
MS patients could be divided in four subgroups based on expression of these genes 
(Satoh et al. 2006). In another study they identified 173 genes in T cells and 50 
genes in non-T cells as differentially expressed between cases and controls. More 
than 80% of the top 30 most significant genes were classified as apoptosis signaling-
related (Satoh et al. 2005). 
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3 Aims of the study 
The aim of this thesis was to elucidate genes and pathways involved in susceptibility 
and pathogenesis of multiple sclerosis. This goal was addressed in three projects, 
with the following specific aims: 
 
I. Testing the association of SNP variants in a candidate gene, MYO9B, with 
multiple sclerosis (Study I). 
 
II. Identifying novel candidate genes and pathways through analysis of 
genome-wide expression in MS patients and controls (Study II, unpublished 
data). 
 
III. Replicating association of CXCR4 with multiple sclerosis (Study III). 
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4 Materials and methods 
4.1 Study samples 
 
The study samples used in studies I-III are presented in Tables 7-9 and Figure 8. 
 
DNA samples 
 
In study I genotyping was first conducted in 730 unrelated Finnish MS cases and 
1425 available family members. 19 families had more than one (2-4) affected 
individual and were therefore informative for linkage. Later, 1325 control samples 
were obtained from unrelated healthy Finnish subjects and genotyped together with 
additional 169 Finnish cases and case-control collections from Denmark, Norway 
and Sweden, which were obtained through collaborators at Copenhagen University 
Hospital, Ullevål University Hospital, Oslo, and Karolinska University Hospital, 
Stockholm. 
 
In study II 803 unrelated patients and approximately 1080 unrelated healthy controls 
were genotyped. 
 
In study III 4104 cases and 4128 controls from Denmark, Norway, Sweden and the 
United Kingdom were genotyped. The Scandinavian samples were obtained through 
the same collaborators as in study I and the samples from United Kingdom through 
collaborators at the University of Cambridge. 
 
All Finnish patients had been previously recruited through the central hospitals in 
Helsinki, Kuopio, Tampere, Oulu, Rovaniemi and Seinäjoki under ethical approval 
from the Helsinki University Hospital Ethical Committee of Ophthalmology, 
Otorhinolaryngology, Neurology and Neurosurgery (permit 192/E9/02). All patients 
had been diagnosed according to Poser's criteria for MS and had provided their 
informed consent. 
 
RNA samples 
 
RNA samples were collected on two occasions in 2006 and 2007. In 2006, a sample 
collection was organised in Helsinki, and PBMCs were collected from 55 MS 
patients (38 females, 16 males) using BD Vacutainer® CPT™ Tubes (Becton, 
Dickinson and Company, NJ, USA). A portion of each sample was further separated 
into CD4+ T cells and non-CD4+ T cells using the magnetic AutoMACS cell 
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separator (Miltenyi Biotec, Germany). In 2007, PBMC samples were collected from 
19 patients in Seinäjoki. Control RNA samples were either obtained from the 
Finnish Twin Study on Ageing (FITSA), an existing collection of samples from 
elderly Finnish female twins, or collected from volunteer female laboratory staff 
members. RNA was extracted from the FITSA PBMCs and Seinäjoki patient 
PBMCs with TRIzol@ (Invitrogen, CA, USA) followed by purification with Qiagen 
Mini Rneasy kit (Qiagen, Hilden, Germany). RNA from PBMCs from the Helsinki 
patients and staff members was isolated with either Qiagen Mini or Qiagen Plus 
Mini Rneasy kits (Qiagen, Hilden, Germany). Sample concentrations and 260/280 
and 260/230 ratios were determined with Nano Drop spectrophotometer (Thermo 
Scientific, DE, USA). The integrity of RNA was confirmed with 2100 Bioanalyzer 
(Agilent, CA, USA). All samples were stored in -80˚C. 
 
Since all control subjects were female, only samples from female patients were 
selected for the microarray experiment and replication stage. 
 
 
Table 7. Study samples in study I. 
 
A. Finnish MS families 
Total Cases 730 
Cases with both parents (and healthy sibling(s)) 340 
Cases with one parent (and healthy sibling(s)) 286 
Cases with no parents, at least 1 healthy sibling 104 
B. Finnish case-controls 
Total Cases 899 
Cases from Finnish MS families 730 
Additional cases 169 
Controls (Helsinki, Kuopio, Seinäjoki) 1325 
C. Combined Scandinavian case-controls 
Total Cases 1521 
Denmark 488 
Norway 348 
Sweden 685 
Total Controls 1476 
Denmark 468 
Norway 369 
Sweden 639 
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Table 8. Finnish samples in study II. SNPs were genotyped in two multiplex 
assays. Control samples genotyped with the first and second multiplex differed by 
96 samples and two different figures are therefore provided. n.a. = not available. 
 
Region Cases Controls 
Seinäjoki 132 365/385 
Helsinki 115 361/413 
Kuopio 98 359/279 
Other (Oulu, 
Rovaniemi, Tampere) 
458 n.a. 
Total 803 1085/1077 
 
 
Table 9. Samples in study III. 
 
Population Cases Controls 
Denmark 580 560 
Norway 617 1018 
Sweden 678 579 
United Kingdom 2229 1971 
Total 4104 4128 
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Figure 8. Samples in the Finnish microarray screen and replication in study II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 THL  –- Research 65/2011 55 Studies on causes of  multiple sclerosis 
 
4.2 Genotyping 
 
Genotyping in studies I and II was conducted using MassARRAY® iPLEX Gold 
genotyping platform, which is based on single nucleotide extension and separation 
of extension products by mass spectrometry (Sequenom, Inc., CA, USA) (Figure 9.). 
Shortly, after amplification of an approximately 100 bp segment of DNA flanking 
the SNP, an extension primer complementary to the sequence just upstream of the 
SNP binds to the amplified fragments and a complementary nucleotide is added at 
the SNP position (single nucleotide extension). The mass of the extension product 
depends on the added nucleotide, i.e. on the SNP allele on the template DNA. The 
extension products are separated by their mass using matrix assisted laser desorption 
ionization time-of-flight (MALDI-TOF) method and the allele(s) can then be 
identified based on the detected mass(es). Genotyping is conducted on 384 well 
plates using multiplex assays with currently up to 40 SNPs. 
 
The Finnish genome-wide SNP data in study II was produced with the Illumina 
HumanHap300 genotyping chip using the Illumina Infinium assay (Illumina, Inc., 
CA, USA). This assay is based on hybridizing a whole-genome amplified sample to 
locus-specific 50-mer probes (covalently bound to beads on the chip), which are 
designed to stop one base before the SNP marker. Following single-base extension 
with differentially labeled nucleotides and fluorescent staining, alleles can be 
detected based on signal intensities. 
 
TaqMan® allelic discrimination technology was used for genotyping in study III. 
Briefly, allele-specific probes recognizing the SNP region and labeled with different 
fluorophores (usually VIC and FAM, for example) at their 5' end are added into the 
PCR reaction with amplification primers flanking the probe binding site. The labeled 
probes also have a so called quencher attached to the 3' end, i.e. a molecule that 
eliminates the fluorophore signal when in close proximity. As the DNA strand 
extension reaches the probe during PCR amplification, Taq DNA polymerase's 5'-
nuclease activity cleaves the probe and as a result, the fluorophore and quencher 
become dissociated and the fluorophore signals become detectable. Genotypes are 
then determined based on signals from the two fluorophores. 
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Figure 9. Sequenom MassARRAY® iPlex Gold genotyping workflow. 
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4.3 Microarray profiling 
 
Genome-wide expression profiling was conducted using the Affymetrix Human 
Genome U133 Plus 2.0 microarray (Affymetrix, CA, USA), which measures the 
expression levels of over 47,000 transcripts, including 38,500 well-characterized 
human genes. Each so called probeset on this chip consists of 11 pairs of 25 bp long 
perfect match (PM) and mismatch (MM) probes, each present as millions of copies 
on each array. The MM probes differ from the PM probes by having the 
complement nucleotide at the 13th nucleotide position and are used for measuring 
unspecific binding. A probeset thereby consists of 22 probes, measuring 11 different 
25-bp sequences within a given transcript. There can be several probesets for a 
single gene, in which case they might measure different splicing- or polyA-variants. 
 
Total RNA samples were prepared for microarrays at two different laboratories by 
their respective staff. All 15 control samples were processed at the Biomedicum 
Biochip Center (BBC) core facility, while 12 patient samples were processed at the 
National Public Health Institute. In addition, one patient sample and technical 
replicates for two patient samples were processed at BBC. BBC equipment was used 
for hybridization, washing and scanning of all arrays. All samples were processed 
according to Affymetrix's recommendations. 
 
4.4 Real-Time polymerase chain reaction 
 
Real-time polymerase chain reaction (Real-Time PCR), also called quantitative PCR, 
is a PCR method based on using either TaqMan® probes labeled with a fluorescent 
dye (see 4.2) or SYBR® Green detector, which is a cyanine dye unselectively 
binding to all double-stranded DNA. The method differs from standard PCR in that 
the amplified product can be detected and quantified by measuring fluorescence at 
each amplification cycle. Because the level of fluorescence depends on the number 
of copies of the target sequence in the sample, the method can be used for estimating 
transcript and DNA copy numbers based on the amplification cycle at which a given 
fluorescence threshold is reached, i.e. the threshold cycle (Ct). In order to account 
for variation in the amount of total DNA or RNA in the reaction, the Ct values are 
corrected using an endogenous control gene such as ACTB, encoding actin protein, 
in which there is assumed to be no quantitative variation between samples. The fold-
difference in the amount of target sequence copies between two samples can then be 
estimated using the comparative Ct method according to: 
 
2^(#Ct(Sample1)-#Ct(Sample2)), 
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where #Ct is the Ct(target gene)-Ct(endogenous control gene). This methods 
assumes, however, that the amplification efficiency is 100%, i.e. that in each cycle 
the amount of amplified product doubles. A more accurate alternative to this method 
would therefore be to use standard curves to quantify the amount of target sequence 
in each sample. 
 
We used Real-time PCR for measuring transcript levels and relative genomic copy 
numbers in study II. In both cases, detection was based on SYBR® Green chemistry 
and amplification was conducted using the ABI7900 thermocycler (Applied 
Biosystems, CA, USA). 
 
4.5 Data analysis 
 
The most frequently used databases and analysis tools are listed in Tables 10 and 11. 
 
Analysis of SNP variants (studies I-III) 
 
Prior to analysis quality control checks were performed to identify any SNPs where 
genotyping problems may have occurred. First, genotyping success rate (percentage 
of samples with successfully called genotype) was assessed and any SNPs with 
success rate <95% were excluded. Second, a test for deviation from Hardy-
Weinberg equilibrium was performed. Hardy-Weinberg equilibrium is the expected 
distribution of genotype counts given the observed allele frequencies in the 
population. Expected distribution is based on the assumption of random Mendelian 
segregation of chromosomes from parent to offspring, and significant deviations 
from this distribution may indicate problems in genotyping or genotype calling. 
Where family data was available, each SNP was also assessed for Mendelian errors, 
i.e. for situations where family members' genotypes are not compatible with 
inheritance. Again, multiple Mendelian errors at a single SNP would indicate 
problems in genotyping or genotype calling. 
 
To test for association in families, two tests were applied. The principle of TDT, 
which requires that both parents of the affected individual have been genotyped, has 
been presented earlier in Figure 4. The TDT test was performed both on single SNPs 
as well as on haplotypes defined using Haploview's solid spine option (Barrett et al. 
2005). Association at individual SNPs was also tested using the gamete-competition 
test (Sinsheimer et al. 2000), which is equivalent to TDT if all parents have been 
genotyped. However, in case of missing data the method estimates these genotypes 
according to their population frequencies. The gamete-competition test is also 
applicable to quantitative traits, and covariates can be incorporated into the analysis. 
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Finally, a non-parametric test for linkage was conducted in 19 families with more 
than one affected individual using the Merlin analysis package (Abecasis et al. 
2002). The test is based on a LOD score calculation method developed by Kong and 
Cox (1997). 
 
In case-control datasets SNPs were tested for association by a two-tailed $2 test with 
one degree of freedom. Furthermore, meta-analyses of datasets were performed by a 
Cochran-Mantel-Haenszel (CMH) test (Mantel 1963) either using PLINK (Purcell et 
al. 2007) or the R 'Stats' package (www.r-project.org/). Because this test assumes 
that the effect of the variant is not significantly different across datasets, a Cochran's 
Q test for homogeneity of ORs (Cochran 1954) was performed before the data was 
combined. The Q test is implemented in R 'meta' package. 
 
Analysis of microarray and Real-Time PCR expression data (study II) 
 
In order to account for technical variation between microarrays (i.e. amount of 
starting RNA, and differences in efficiencies of reverse transcription, labeling and 
hybridization), raw signal intensities were first normalized. In this study, the data 
was normalized using the GC-RMA method available in GeneSpring 7.3 (Agilent, 
CA, USA). GC-RMA is a modification of the RMA (Robust Multi-Array) 
normalization method, but unlike RMA it takes into account the GC content of a 
probe (GC rich sequences are expected to show higher intensities due to a higher 
binding efficiency). Both RMA and GC-RMA perform a simultaneous within- and 
between-array normalization across all arrays in a given set and summarize signals 
of the 11 individual probes to a normalised probeset signal, which is used in the 
actual analysis. 
 
After normalisation the data was filtered in order to exclude probesets with low 
expression and/or affected by differences between the laboratories (see Figure 13 
under 5.2.1 for details). Differentially expressed genes (DEG) were identified by 
comparing average expression levels in cases and controls and by conducting a non-
parametric Mann-Whitney test to obtain P-values for statistical significance. This 
test does not make any assumptions about distribution of data like parametric tests 
such as t-test, which should only be applied to normally distributed datasets. P-
values were then corrected for multiple comparisons using Benjamini-Hochberg 
false discovery rate (FDR). All filtering steps and statistical analyses were 
conducted using GeneSpring 7.3. 
 
Finally, pathway analysis was performed using the Core Analysis option in 
Ingenuity Pathway Analysis (IPA) tool (Ingenuity Systems, Inc., CA, USA). This 
option tests for association between a user-provided list of genes and genes in 
canonical pathways stored in IPA by performing Fisher's exact test, which provides 
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a probability that the given genes are associated with the genes in the pathway by 
chance alone.  
 
Statistical significance for difference in gene expression between cases and controls 
in data obtained by Real-Time PCR was evaluated by Mann-Whitney test. 
 
 
Table 10. Most frequently used databases. Website is provided if the database is 
freely accessible through this site. 
 
Name (reference if 
available) 
Website Studies in which used 
eQTL Browser http://eqtl.uchicago.edu/Home.html II 
GeneCards http://www.genecards.org I-III 
Gene Expression 
Omnibus 
http://www.ncbi.nlm.nih.gov/geo II 
GHS_Express (Zeller 
et al. 2010) 
http://genecanvas.ecgene.net/uploads/ForReview II 
HapMap (International 
HapMap Consortium 
2005) 
http://hapmap.ncbi.nlm.nih.gov I-III 
mRNA by SNP 
Browser (Dixon et al. 
2007, Moffatt et al. 
2007) 
http://www.sph.umich.edu/csg/liang/asthma II 
NetAffx http://www.affymetrix.com/analysis/index.affx II 
UCSC Genome 
Browser 
http://genome.ucsc.edu/ I-III 
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Table 11. Most frequently used analysis tools. Website is provided if the tool is 
freely accessible through this site. 
 
Name (reference if 
available) 
Website if available Studies in 
which 
used 
AssayDesign (Sequenom, 
Inc., CA, USA) 
 I,II 
GCOS (Affymetrix, CA, 
USA) 
 II 
Genetic Power Calculator 
(Purcell et al. 2003) 
http://pngu.mgh.harvard.edu/~purcell/gpc I-III 
GeneSpring (Agilent, CA, 
USA) 
 II 
Haploview (Barrett et al. 
2005) 
http://www.broadinstitute.org I-III 
Ingenuity Pathway 
Analysis (Ingenuity 
Systems, Inc., CA, USA) 
 II 
Mendel (Lange et al. 2001) http://www.genetics.ucla.edu/software/mendel I 
PedCheck (O'Connell and 
Weeks 1998) 
http://watson.hgen.pitt.edu/register/docs/pedcheck.html I 
PLINK (Purcell et al. 
2007) 
http://pngu.mgh.harvard.edu/~purcell/plink/gplink.shtml I-III 
Primer3 (Rozen and 
Skaletsky 2000) 
http://frodo.wi.mit.edu/primer3 II 
R software environment http://www.r-project.org II 
SDS 2.2 (Applied 
Biosystems, CA, USA) 
 II,III 
SNP Annotation and Proxy 
Search (SNAP) (Johnson et 
al. 2008) 
http://www.broadinstitute.org/mpg/snap II 
SNPper (Riva and Kohane 
2002) 
http://snpper.chip.org I,II 
TypeAnalyzer (Sequenom, 
Inc., CA, USA) 
 I,II 
 THL  –- Research 65/2011 62 Studies on causes of  multiple sclerosis 
 
 
5 Results and discussion 
5.1 Testing association of MYO9B variants with MS (study I) 
5.1.1 Association analysis in Finnish trios 
 
At the time of initiating this project in 2005, replicated associations of SNP variants 
in MYO9B encoding myosin IXB protein had been reported in CD and UC 
(Monsuur et al. 2005, van Bodegraven et al. 2006). With the hypotheses that the 
same variants or loci may predispose to different autoimmune diseases, in the first 
part of this thesis the role of MYO9B in MS was investigated. While the previously 
reported associations mapped to the 3' end haploblock of MYO9B, variants from the 
entire gene were included in this study, taking into account the possibility of allelic 
heterogeneity. 
 
First, 18 SNPs were genotyped in 730 Finnish MS families (Figure 10). Because 
these included only 340 full trios, i.e. trios where both parents had been genotyped, a 
Gamete Competition test which is able to use families with missing genotypes, was 
conducted in addition to TDT test which only uses full trios. No significant 
association was observed and only a single nominally significant association with a 
relatively rare variant (MAF=0.09) was identified (P-value =0.03). 
 
The families were then stratified according to a previously identified two-SNP risk 
haplotype in the PRKCA gene (defined by SNPs rs887797 and rs1010544), which at 
that time was the only non-MHC risk variant identified in the Finnish population. 
There was also a function-based rationale behind this stratification: MYO9B protein 
is known to downregulate RhoA (Post et al. 1998), which is central in a pathway 
regulating brain endothelial permeability, and this pathway also involves PRKCA 
(Stamatovic et al. 2006) (Figure 11). After stratification, a significant association 
with the SNP rs12986130 was identified in families where the patient did not carry a 
copy of the PRKCA risk allele (P-value =0.0001) (A.K. et al. unpublished results). 
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Figure 10. Haploblock structure of MYO9B in HapMap CEPH samples. Figure 
was produced with Haploview (Barrett et al. 2005). SNPs genotyped in all samples 
are indicated with black arrows and SNPs genotyped only in Finnish MS families 
are marked with grey arrows. SNPs associated with CD or UC are marked with 
asterisks. Colouring indicates the extent of linkage disequilibrium (LD) between 
SNP pairs, based on r2 as the measure of LD. Darker color indicates higher LD. 
Haploblocks, i.e. regions of relatively high LD between SNPs, are defined with 
triangles. In this case haploblocks were defined using the “solid spine” option, 
which identifies blocks so that the first and last SNPs in a block are in strong LD 
with all intermediate markers, but these intervening markers are not necessarily in 
LD with each other. 
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Figure 11. A potential scenario depicting how MYO9B may be involved in 
regulating BBB permeability via a CCL2 induced pathway. Modified from 
Stamatovic et al. (2006) by adding MYO9B, which is known to down-regulate 
RhoA (Post et al. 1998). Chemokine CCL2 binds to its receptor CCR2, which is 
present on surface of brain endothelial cells. This results in activation of RhoA 
which further activates Rho kinase and PRKCA. Rho kinase then induces the 
reorganization of cell actin cytoskeleton and tight junction proteins, which connect 
brain endothelial cells, while PRKCA causes direct phosphorylation of tight junction 
proteins and their redistribution. As a result, brain endothelial barrier permeability is 
increased, which facilitates leukocyte movement into CNS. CCL2=chemokine (C-C 
motif) ligand 2, CCR2=chemokine (C-C motif) receptor 2, PRKCA=protein kinase 
C alpha, RhoA=Ras homolog gene family, member A. 
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5.1.2 Association analysis in Northern European cases and controls 
 
Acknowledging the low power of the family sample to detect association at variants 
with modest effect sizes, and in order to further investigate the potential PRKCA-
MYO9B interaction, 10 of the variants (a single multiplex) were tested for 
association in a larger sample of 2420 cases and 2801 controls from Finland, 
Denmark, Norway and Sweden. No significant association was observed in any 
individual population or in a Cochran-Mantel-Haenszel-test treating populations as 
separate strata. The cases were then stratified according to the PRKCA risk allele 
carrier status by using two-SNP genotype combinations, and rs12986130 was tested 
for association with MS in the risk allele negative group. No significant association 
was observed in any individual population or in CMH-test. 
 
5.1.3 Discussion 
 
Although the results presented above do not provide support for a major role of 
MYO9B variants in MS, the possibility of an epistatic effect between PRKCA and 
MYO9B and its role in MS cannot be completely excluded. Neither gene has been 
reported in recent MS GWASs, but again this does not exclude the role of their 
potential interaction. However, as the initial finding in Finnish families suggesting 
association of MYO9B after conditioning on PRKCA MS-risk haplotype was not 
replicated, it is unlikely that this finding was a true positive. 
 
Regarding the suggested role of MYO9B in other autoimmune diseases, after the first 
report of MYO9B association with CD (Monsuur et al. 2005), four studies have 
found association at MYO9B variants with inflammatory bowel disease (IBD, UC 
and/or ChD) (van Bodegraven et al. 2006, Núñez et al. 2007, Cooney et al. 2009, 
Latiano et al. 2008), one study with schizophrenia (Jungerius et al. 2008), one with 
refractory CD (Wolters et al. 2007), one with T1D (Santiago et al. 2008), and one 
study with CD, SLE and/or RA (Sánchez et al. 2007). On the other hand, six studies 
in CD (Latiano et al. 2007, Cirillo et al. 2007, Núñez et al. 2006, Giordano et al. 
2006, Amundsen et al. 2006a, Hunt et al. 2006), one in UC (Amundsen et al. 2006b) 
and one in T1D (Persengiev et al. 2010) failed to find association. In addition, a 
Finnish-Hungarian study failed to find association with CD, although evidence for 
linkage was found (Koskinen et al. 2008). As of today, no functional studies have 
been conducted to further explore the potential role of MYO9B gene in these 
diseases, and according to the GWAS Catalogue 
(http://www.genome.gov/gwastudies/) the gene had not been identified in any 
GWASs (August 2011). 
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In conclusion, these results do not provide support for a major role of the tested 
MYO9B variants in MS, although the study would have been underpowered to detect 
association at these variants if their effect sizes were low, especially in case of SNPs 
with a relatively low MAF (Figure 12). For example, assuming homozygote OR 
=1.3 the power to detect association at a variant with RAF =20% was reasonable, 
80%, but at a variant with RAF =5% only 35%. Therefore the power to detect 
association at two of the ten tested variants, in which MAF was <5%, was low 
unless their homozygote ORs were >1.5. With a lower homozygote OR =1.2 the 
power did not exceed ~60% even at common variants. Finally, as the SNPs 
genotyped in this study captured only approximately 50% of common variation 
(MAF %0.05) in the gene with r2 %0.7, the role of remaining MYO9B variants in MS 
cannot be excluded. 
 
 
 
 
 
Figure 12. Power to detect association in the Northern European sample for 
different risk allele frequencies (RAF) as a function of risk allele homozygote 
OR. 
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5.2 Identifying MS-related genes and pathways through 
studies of genome-wide association (study II and unpublished 
results) 
 
5.2.1 Finnish microarray study 
 
In the second study the aim was to identify novel MS candidate genes and pathways 
through genome-wide expression profiling. First, a study in PBMC samples from 12 
Finnish MS patients and 15 controls was performed. Outline of this study is 
presented in Figure 13. In this screen, 926 probesets showing a minimum fold 
change of 1.5 in average signal between cases and controls and statistically 
significant after correcting for multiple testing were identified. Only 692 of these 
had an unambiguous gene annotation based on comparing annotations obtained from 
GeneSpring and NetAffx. Of these, 301 probesets were upregulated and 392 
downregulated in MS patients. Surprisingly, three of the four most strongly 
upregulated genes (CLC, DEFA1A3 and LTF) are known to be highly expressed in 
granulocytes. Pathway analysis using IPA was also conducted on the DEGs and 
revealed a strong association with several pathways including PI3K signaling in B-
lymphocytes and B cell development pathways (Table 12). 
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Figure 13. Summary of the microarray study. To exclude probesets with low 
expression, all probesets in which normalised signal was <50 in at least 20 of 27 
arrays were filtered out. To further exclude probesets potentially affected by 
technical factors, also probesets in which the expression showed >1.4-fold 
difference between the technical replicates in both replicate pairs were excluded. In 
addition, probesets where the signal in all three MS samples prepared at the BBC 
ranked among the four lowest or four highest among the MS samples were excluded. 
It is acknowledged that these criteria are arbitrary. However, whereas before 
filtering the technical replicates from the same sample clustered apart and the 
samples seemed to primarily cluster according to where the samples had been 
processed, after filtering the technical replicates clustered together, suggesting that 
the filtering steps were successful in removing a significant fraction of probesets in 
which the signal may have been affected by technical factors. 
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Table 12. Top 20 canonical pathways associated with genes showing differential 
expression in MS in the Finnish microarray study. 
 
Pathway P-value 
PI3K Signaling in B Lymphocytes 1.3E-06 
B Cell Development 2.6E-06 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 3.4E-06 
Role of PKR in Interferon Induction and Antiviral Response 4.6E-05 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 7.8E-05 
Death Receptor Signaling 1.2E-04 
CD27 Signaling in Lymphocytes 3.4E-04 
NF-&B Activation by Viruses 3.6E-04 
Molecular Mechanisms of Cancer 3.9E-04 
Glucocorticoid Receptor Signaling 4.4E-04 
CD28 Signaling in T Helper Cells 4.6E-04 
Dendritic Cell Maturation 5.0E-04 
B Cell Receptor Signaling 5.0E-04 
Type I Diabetes Mellitus Signaling 5.1E-04 
TREM1 Signaling 5.2E-04 
Sphingosine-1-phosphate Signaling 5.5E-04 
Role of NFAT in Regulation of the Immune Response 5.8E-04 
TNFR1 Signaling 6.8E-04 
Apoptosis Signaling 9.8E-04 
Induction of Apoptosis by HIV1 1.0E-03 
Graft-versus-Host Disease Signaling 1.2E-03 
Breast Cancer Regulation by Stathmin1 1.2E-03 
CD40 Signaling 1.3E-03 
IL-8 Signaling 1.4E-03 
Fc!RIIB Signaling in B Lymphocytes 1.6E-03 
Docosahexaenoic Acid (DHA) Signaling 1.6E-03 
fMLP Signaling in Neutrophils 1.7E-03 
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5.2.2 Integrating results from the Finnish microarray study and a 
Finnish GWAS (A.K. et al. unpublished results) 
 
The list of DEGs was then compared with results from a Finnish GWAS, which had 
just been completed using the Illumina 300K platform (Jakkula et al. 2010). This 
study included 68 MS patients from a high risk subisolate in Southern Ostrobothnia 
and 136 genetically matched controls. Most patients could be traced back to one of 
two common ancestor couples in the 16th century, and it was therefore hypothesised 
that this sample would be enriched for shared MS susceptibility alleles. Of SNPs 
mapping within 100 kb of our DEGs, 20 with an association P-value <0.001 in the 
GWAS were identified. Eight of them mapped within 20 kb of their annotated gene 
and were included in replication in a more heterogeneous Finnish sample of 803 
cases and ~1080 controls. However, none of the six successfully genotyped SNPs 
were replicated with statistical significance in the entire Finnish sample or in an 
expanded Southern Ostrobothnian sample apart from the SNP at C6orf136, which is 
located between MHCI and MHCII loci. This signal was therefore likely to reflect 
association coming from the MHCII risk variant, and indeed association at C6orf136 
was only seen in patients with at least one copy of the MS risk allele HLA-
DRB1*1501. 
 
5.2.3 Follow-up of findings from the Finnish microarray study (A.K. et al. 
unpublished results) 
 
Replication 
 
In order to experimentally confirm some of the findings from the Finnish microarray 
study, five genes were selected for replication by Real-Time PCR in 30 MS patients 
and 30 controls. DEFA1A3 and IGHM were selected to represent granulocyte- and B 
cell-related genes, respectively, many of which were showing increased expression 
in MS in the microarray study. Of the genes showing increased expression in MS 
also IL8, which encodes interleukin 8, a cytokine acting as a chemotactic factor for 
various immunological cells and increasing migration of monocytes across BBB in 
vitro, was selected (Yang et al. 2009). Of the genes showing decreased expression in 
MS LILRA4 and TNFRSF25 were selected. LILRA4 encodes a leukocyte-
immunoglobulin-like receptor alpha 4, which is located in the leukocyte receptor 
gene cluster on 19q13. Many of the genes in this cluster bind with MHCI molecules 
and thereby likely play a role in antigen presentation (Brown et al. 2004). The ligand 
for LILRA4 is unknown but interestingly MHCII encoded molecules have been 
suggested as potential candidates. TNFRSF25 has been suggested to be involved in 
removal of auto-reactive T cells in the thymus (Wang et al. 2001). 
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Of the five genes, expression differences in DEFA1A3, LILRA4 and TNFRSF25 
were statistically significant between cases and controls (Figure 14). In addition, IL8 
showed a 1.6-fold difference in expression between cases and controls, but the 
difference was not statistically significant. IGHM showed higher expression in MS 
patients in comparison with controls from the FITSA collection, but lower 
expression in comparison with control samples collected from staff members. This 
may suggest an age-related effect, since the average age in MS patients was lower 
than in FITSA controls, but higher than in staff controls. Unfortunately it was not 
possible to test the IGHM transcript levels in age-matched controls. 
 
 
 
Figure 14. Results from Real-Time PCR replication. The replication set included 
30 MS patient samples and 30 controls samples. Y-axis shows the negative of ACTB 
corrected Real-Time PCR Ct values such that expression increases along the axis. A 
difference of a single unit represents a two-fold difference in expression. 
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Analysis of genetic variants 
 
The role of common CNV and SNP variants in DEFA1A3, IL8, LILRA4 and 
TNFRSF25 in MS was then tested. First, common SNP variants in IL8, LILRA4 and 
TNFRSF25 were investigated, while DEFA1A3 was excluded due to previously 
reported extensive copy number variation in the general population (Aldred et al. 
2005, Linzmeier et al. 2005). The selected SNPs tag 100%, 73% and 80% of 
variation within 5 kb of IL8, LILRA4 and TNFRSF25, respectively, with r2 >0.7. No 
significant association was observed in 803 Finnish cases and ~1080 controls 
although two SNPs, one in TNFRSF25 and one in LILRA4, were nominally 
significant (uncorrected P-values <0.05) (Table 13). Because some of the cases did 
not have geographically matched controls in the available control set, which may 
have distorted the result, these two SNPs were further tested in geographically 
matched subsets. A meta-analyses of samples from Southern Ostrobothnia, Southern 
Finland and Savonia revealed a significant association with LILRA4 SNP 
rs11084330 (uncorrected CMH P-value =0.002). Interestingly, evidence was also 
found for an epistatic interaction between this variants and HLA-DRB1*1501 in 
cases (PLINK epistasis option P-value =0.02), but not in controls. It was then tested 
whether rs11084330 correlates with LILRA4 transcript levels. Both genotype and 
Real-Time PCR expression data was available for 41 MS patients. No significant 
difference in LILRA4 expression between individuals with no risk allele versus 
individuals with at least one risk allele was detected. Finally, rs11084330 was tested 
for association with MS in 3372 patients and 3720 controls from Denmark, Norway 
and Sweden. There was no significant association in any individual population or in 
meta-analysis of all four populations, when including Finland. There was also no 
evidence for an epistatic interaction with HLA-DRB1*1501 in cases from Denmark 
and Norway. HLA information was not available for the Swedish cases. 
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Table 13. Results from association analysis of IL8, LILRA4 and TNFRSF25. 
 
Whole Finland Gene SNP Alleles 
Major:Minor 
MAF 
Cases 
MAF 
Controls 
P-value 
CMH P-value in three 
geographically 
matched subsets 
IL8 rs2227306 C:T 0.39 0.38 0.65 - 
TNFRSF25 rs3138158 C:T 0.09 0.11 0.17 - 
TNFRSF25 rs3138156 T:C 0.10 0.08 0.02 0.25 
TNFRSF25 rs2986754 C:G 0.04 0.03 0.33 - 
LILRA4 rs7259731 G:T 0.15 0.14 0.62 - 
LILRA4 rs6417165 C:T 0.21 0.20 0.24 - 
LILRA4 rs1205322 A:G 0.33 0.33 0.99 - 
LILRA4 rs11084330 A:G 0.20 0.17 0.01 0.002 
LILRA4 rs7253755 C:T 0.14 0.16 0.35 - 
LILRA4 rs7257994 T:C 0.17 0.18 0.33 - 
LILRA4 rs3745419 T:A 0.17 0.18 0.45 - 
LILRA4 rs10419832 T:C 0.12 0.12 0.75 - 
LILRA4 rs2241385 T:C 0.30 0.32 0.16 - 
LILRA4 rs8102662 A:G 0.49 0.48 0.51 - 
LILRA4 rs8103715 T:C 0.36 0.37 0.28 - 
LILRA4 rs10426462 T:C 0.37 0.37 0.86 - 
LILRA4 rs4356595 G:C 0.37 0.37 0.72 - 
LILRA4 rs2004431 T:G 0.12 0.10 0.07 - 
LILRA4 rs1106659 C:A 0.34 0.37 0.08 - 
 
 
CNVs had previously been reported in DEFA1A3, LILRA4 and TNFRSF25 (Iafrate 
et al. 2004, Database of Genomic Variants, http://projects.tcag.ca/variation/). It was 
therefore tested whether CNVs could contribute to their altered expression in MS. 
The relative genomic copy number was determined in 18 patients and 18 controls, 
for which transcript levels had been previously determined and showed a significant 
difference between the two groups (Figures 15-17). It is not clear whether there were 
CNVs in LILRA4 and TNFRSF25 or whether the observed variance in #Ct 
represented technical variation. While LILRA4 and TNFRSF25 are expected to be 
present as two copies in the vast majority of individuals in the population, the 
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absolute genomic copy numbers of DEFA1A3 (which in fact is a locus with a 
variable number of copies of two nearly identical genes, DEFA1 and DEFA3) in the 
normal population have been shown to range from 5 to 14 in one study with 25% of 
people lacking DEFA3 completely (Linzmeier and Ganz 2005), and from 4 to 11 in 
another study, in which approximately 10% lacked DEFA3 (Aldred et al. 2005). 
Because reference samples with known DEFA1A3 copy numbers were not available, 
determining the absolute copy numbers was not possible. Even with reference 
samples, the Real-Time PCR based method would not be sensitive enough to detect 
a difference between 8 and 10 copies, for example, as it's sensitivity is roughly 
limited to detecting 2-fold differences (for example, 2, 4, 8, 16 copies etc.). 
However, based on variance in #Ct, the DEFA1A3 copy number seemed to vary in 
the investigated samples, although there was no correlation between #Ct(mRNA) 
and #Ct(genomic DNA), or any significant difference in the average #Ct(genomic 
DNA) between cases and controls in any of the three genes. This would indicate that 
CNVs are not responsible for the detected differences in gene expression between 
these cases and controls. The lack of correlation between copy number and 
expression in DEFA1A3, as shown in Figure 15, is consistent with previous findings 
by Aldred et al. (2005). 
 
 
 
 
Figure 15. DEFA1A3 expression levels as a function of genomic copy number. 
Values were scaled relative to the sample with lowest expression/copy number. For 
example, a sample with a relative copy number of 500 has a 500-fold expression 
compared to the sample with the lowest DEFA1A3 expression. Linear regression 
lines are shown separately for cases and controls. 
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Figure 16. LILRA4 expression levels as a function of genomic copy number. See 
Figure 15 legend for explanation. 
 
 
 
 
Figure 17. TNFRSF25 expression levels as a function of genomic copy number. 
See Figure 15 legend for explanation.  
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5.2.4 Systematic review of genome-wide expression studies in MS 
 
In order to identify DEGs reported in several independent studies, genes reported as 
differentially expressed in MS in six previously published microarray experiments 
and the study described in 5.2.1 were listed. 229 genes were identified in at least two 
of the seven studies as either up- or downregulated. 11 of these in silico replicated 
genes were reported in three studies and one, HSPA1A, in four studies. Because the 
study described in 5.2.1 included some treated patients and may also have been 
confounded by the difference in average age between cases and controls as well as 
by technical differences in treating the samples, a systematic review was also 
conducted excluding this study. 135 genes remained as having been reported in at 
least two studies. 
 
Pathway analysis on both the 135 and 229 DEGs revealed several highly 
significantly associated pathways, many of which are immune-related. The most 
highly significant pathway associated with both gene lists was the glucocorticoid 
receptor signaling pathway. Among the top findings were also several interleukin 
signaling pathways (IL-4, IL-6, IL-17), of which the IL-6 signaling pathway is 
shown in Figure 18 (the glucocorticoid receptor signaling pathway is too complex to 
be shown here). 
 
The list of 229 DEGs was then compared to loci showing evidence of association (P-
value "0.0001) in five previously published MS GWASs (ANZgene 2009, Baranzini 
et al. 2009, De Jager et al. 2009, IMSGC et al. 2007, Jakkula et al. 2010). Including 
all SNPs mapping within 100 kb of a DEG, 15 non-MHC loci with association P-
value "0.0001 were found. These include three loci associated with MS with GWS: 
CDK4, IL7R and TNFRSF1A. None of the potent risk variants in these 15 loci 
correlated significantly with expression of the corresponding gene according to the 
mRNA by SNP Browser or the monocyte study by Zeller et al. (2010) apart from 
CD40, where the risk variant was, however, associated with lower expression of the 
gene, while higher expression in MS was reported in the expression studies. In 
addition, of the top 102 loci identified in the IMSGC and WTCCC2 GWAS 
(IMSGC and WTCCC2 2011), seven mapped within 100 kb of the 229 DEGs, of 
which NFKB1 and SAPS2 were not already listed among the 15 genes identified 
above. A correlation was seen between the risk variant near SAPS2 and SAPS2 
expression in lymphoblastoid cell lines (mRNA by SNP Browser), and the effect 
was consistent with the increased expression of SAPS2 in MS. Expression between 
risk allele carriers and non-carriers in the 17 genes was also compared using data 
from a lymphoblastoid cell line expression dataset from 60 HapMap CEPH parents 
(Spielman et al. 2007). Only CXCR4 showed evidence for a difference in expression 
between risk allele carriers and non-carriers, with higher expression in the first 
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group (uncorrected one-sided Mann-Whitney test P-value =0.03). A concordant 
trend was also observed in the microarray dataset described in 5.2.1 (One-sided 
Mann-Whitney test P-value =0.06). 
 
 
 
Figure 18. IL-6 signaling pathway. From Ingenuity Pathway Analysis (IPA) 
(Ingenuity Systems, Inc., CA, USA). Nodes shown in grey are among the in silico 
replicated 229 DEGs. Printed with permission. 
 THL  –- Research 65/2011 79 Studies on causes of  multiple sclerosis 
 
5.2.5 Discussion 
 
In this part of the thesis a genome-wide expression study was first conducted to 
identify genes with differential expression in MS, followed by replication and 
genetic studies in selected genes. In addition, a systematic review of seven studies 
on gene expression in MS was performed and the most consistent findings were 
analyzed in the context of published GWASs and using pathway analysis tools. 
 
The conducted microarray study identified 609 DEGs, although it is likely that many 
of these could be false positives due to the small sample size and effects of 
confounding factors (difference in age of patients and controls, technical differences 
in sample processing). Three of five genes selected for replication in a larger 
independent sample were successfully replicated: DEFA1A3, LILRA4, and 
TNFRSF25. However, none of these showed any evidence of association with MS, 
nor have they emerged in published GWASs. This would suggest that their 
differential expression in MS is unlikely to be due to cis-acting common risk 
variants. 
 
DEFA1A3, a copy number variable locus which contains two nearly identical genes, 
DEFA1 and DEFA3 (in this study it was not possible to distinguish between the 
expression of these two genes), showed highly increased expression in MS. These 
genes have previously been reported to be over-expressed on mRNA or protein level 
not only in MS, but also in SLE, T1D and IBD (Bennett et al. 2003, Ishii et al. 2005, 
Saraheimo et al. 2008, Sthoeger et al. 2009, Yamaguchi et al. 2009). The genes 
encode alpha defensins 1 and 3, which are secreted by neutrophils and can inactivate 
bacteria, fungi and viruses (Ganz et al. 1985). It is possible that a higher expression 
of DEFA1A3 in MS could reflect a higher amount of granulocyte contamination in 
PBMC samples, potentially as a result of elevated levels of granulocytes in their 
peripheral blood. However, this is not supported by the observation that only one of 
26 neutrophil markers identified by Whitney et al. (2003) showed significantly 
increased levels in MS in the microarray experiment. 
 
The second replicated gene, LILRA4, is a marker for pDCs, a class of specialized 
DCs which produce high levels of type I interferons (Ju et al. 2004, Cho et al. 2008). 
LILRA4 is downregulated when pDCs mature in response to viral or bacterial 
stimulation (Ju et al. 2004). It is therefore possible that the lower expression of 
LILRA4 observed in MS patients could reflect lower levels of pDCs or higher pDC 
stimulation. pDCs are important in regulating peripheral T cell tolerance and in MS 
there is evidence for imbalance in two pDC subsets, which differentially induce Th2 
and Th17 cells (Schwab et al. 2010). Whether LILRA4 plays a role in causing this 
imbalance remains to be studied. 
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Finally, we replicated the decreased expression of full-length isoform of TNFRSF25 
in MS. This isoform encodes a transmembrane protein with a death-domain, which 
can transmit apoptotic signals (Screaton et al. 1997) and has been shown to be 
involved in regulating removal of auto-reactive thymocytes (Wang et al. 2001). The 
shorter isoforms encoding soluble proteins did not show differential expression in 
MS in our microarray screen and were not investigated in replication samples. 
 
In order to identify additional DEGs supported by evidence from several 
experiments, six previously published expression studies were reviewed. 132 of the 
609 DEGs (22%) found in the expression study described in this thesis had been 
identified in at least one other study. In the other six studies, the percentage of 
reported DEGs identified in other studies ranged from 11% to 47%. Most studies 
were relatively small (10-30 samples per group), which together with differences in 
the immune cells included in the profiling (whole blood, PBMCs, T cells, non-T 
cells) is likely to explain the poor overlap between studies. Only 11 genes had been 
reported to be differentially expressed in MS in three studies and only one gene, 
HSPA1A, in four studies. The HSPA1A gene is located in the Major 
Histocompatibility Complex Class III (MHCIII) region between MHCI and MHCII, 
and encodes a 70kDa heat shock protein HSP70-1A, which is part of the HSP70 
chaperone. The HSP70 chaperone system is involved in various immunological 
processes: extracellular HSP70 can initiate innate immune responses, acting as a 
cytokine-like factor, while cellular HSP70 is involved in antigen presentation and 
thereby in the activation of the adaptive immune system (Chen and Cao 2010). How 
a lower expression of HSPA1A could relate to MS pathogenesis remains to be 
studied, but one possibility is that a reduced capacity to present auto-antigens to 
developing T cells in the thymus could result in impaired negative selection and 
increased release of auto-reactive T cells to the periphery. 
 
Given that many disease risk variants are likely to affect gene expression, findings 
from expression studies were compared with those from GWASs. Suggestive 
evidence of association had been reported in 17 of the 229 DEGs, but only in case of 
SAPS2 there was evidence for an effect of the risk variant on gene expression based 
on the mRNA by SNP Browser (listing eQTLs with P-value <0.001) or the 
GHS_Express monocyte eQTL database (Zeller et al. 2010) (listing eQTLs with P-
value <0.00001). Not much is known about the function of SAPS2, but it has been 
shown to interact with NFKBIE (Stefansson and Brautigan 2006), which is an 
inhibitor of transcription factor NF-&B and is involved at least in regulating T cell 
proliferation and B cell differentiation (Doerre et al. 2005, Tergaonkar et al. 2005, 
Wang et al. 2008). The associated SNP is located 90 kb downstream of the gene 
next to a CpG island (according to the UCSC Genome Browser). It may therefore 
well be related to regulation of gene expression, although none of the eight genes 
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located between the SNP and SAPS2 were among the 229 DEGs. Finally, in order to 
detect more modest SNP-expression correlations the 17 genes were examined in an 
expression dataset from 60 HapMap CEPH parents. Unfortunately SAPS2 was not 
represented on this expression array. However, there was nominally significant 
evidence for higher CXCR4 expression in carriers of the suggestively associated 
variant near CXCR4. Based on consistent data from the microarray study described 
in 5.2.1., it seems that the increased expression of CXCR4 in MS may be contributed 
to alternative polyadenylation, because a difference in expression between patients 
and controls was only seen with a probeset extending to the 3’ UTR and not with 
probesets measuring exonic sequences. However, the CXCR4 risk variant is located 
relatively far from the gene (100 kb upstream) with no high LD to SNPs within the 
gene, and it is therefore not clear how it would affect its polyadenylation. 
 
Although there was no evidence for correlation between the potent MS susceptibility 
variant and gene expression in the other 15 genes in available datasets, large studies 
in different cell populations can be expected to reveal additional correlations in the 
future. However, the overall limited overlap between the 229 DEGs and loci 
identified in GWASs would suggest that the altered expression in most of the DEGs 
identified is not explained by genetic MS risk variants. Instead, some of these 
findings may reflect immunological processes activated during MS. The DEGs 
identified in more than one study were significantly associated with several 
immunological pathways including the glucocorticoid receptor signaling pathway 
which is important in controlling inflammation, and several interleukin signaling 
pathways (IL-4, IL-6, IL-10, IL-17) which are primarily related to Th2, and Th17 
cells and Tregs: IL-4 and IL-10 are secreted by Th2 cells (Cherwinski et al. 1987, 
Fiorentino et al. 1989), IL17-production is characteristic for Th17 cells (Harrington 
et al. 2005, Park et al. 2005) and IL-6 regulates differentiation of naive T cells into 
Th17 cells while inhibiting their differentiation into Tregs (Bettelli et al. 2006) 
However, at this stage not much more can be concluded from these findings and it 
should be further investigated whether these pathways are differentially regulated in 
MS patients already prior to disease onset, or whether their altered activity is a 
secondary phenomena. 
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5.3 Replicating association of a variant in CXCR4 locus with 
MS (study III) 
 
Based on findings in the second part of this thesis, where a modest correlation 
between CXCR4 expression and a suggested MS risk variant located 100 kb 
upstream was found, in the final part of the thesis the aim was to replicate the 
association of this variant, rs8823000, with MS. This variant showed strong 
evidence of association with MS in two previous studies, although it did not reach 
GWS (De Jager et al. 2009, IMSGC 2010a). In this thesis, the association of 
rs882300 with MS was replicated in a total of 4104 MS cases and 4128 controls (P-
value =0.0004). However, the association was not confirmed with GWS even when 
combining with allele counts from 8085 cases and 7777 controls genotyped in a 
previous study (IMSGC 2010a) (P-value =1.8E-07). 
 
Public eQTL databases (mRNA by SNP Browser, eQTL Browser and the monocyte 
eQTL database by Zeller et al. 2010) were then searched for evidence of correlation 
between rs882300 or its tagging SNPs (r2 >0.8) and CXCR4 expression (as of April 
2011), but no reported correlations were found. Furthermore, there was no evidence 
of correlation in 585 whole blood samples (data from study by Inouye et al. 2010, 
personal communication with J. Kettunen, National Institute for Health and Walfare, 
Helsinki, Finland). However, none of the eQTL studies conducted in immune cells 
or lymphoblastoid cell lines were performed with a platform that would have 
measured CXCR4 expression at its 3’ UTR, where evidence for a difference in 
expression between risk allele carriers and non-carriers was seen in study II. Data 
from the published eQTL studies is therefore not contradictory to the observation in 
study II, although given the location of rs882300 100kb upstream of CXCR4 with no 
known correlating variants in the 3’ UTR, its effect on alternative polyadenylation 
doesn’t seem very likely. It is also possible that rs882300 exerts its effects via some 
other gene than CXCR4, although none of the other genes within 1 Mb (ZRANB3, 
R3HDM1, MIR128-1, UBXN4, LCT, MCM6, DARS, THSD7B) have any known 
immunologically or neurologically relevant functions.  
 
CXCR4 is an excellent MS candidate gene as it plays a role in various 
immunological and neurological processes, including thymic selection and T cell 
differentiation (Suzuki et al. 1998, Plotkin et al. 2003), B-lymphopoiesis and 
humoral immunity (Ma et al. 1998, Nie et al. 2004), and cerebellar development 
(Ma et al. 1998, Zou et al. 1998). CXCR4 and its ligand CXCL12 have also been 
shown to promote trans-endothelial migration of T cells in vitro (Liu et al. 2009), 
while antagonists for CXCR3 and CXCR4 inhibit EAE pathogenesis and reduce 
accumulation of CD4+ T cells in CNS (Kohler et al. 2008). Although the association 
of rs882300 with MS did not reach GWS, it is very likely to be a true MS 
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susceptibility variant given the consistency of association signal in several 
independent populations. 
 
 
5.4 General discussion 
 
In 2005 when this thesis was started, candidate gene studies were the only available 
approach for identifying SNPs associated with complex traits. Just six years later 
hundreds of GWASs have been conducted in a number of complex traits and have 
proven successful in identifying new disease risk variants, including close to fifty 
variants associated with MS. While the most important outcome of the hypotheses-
free GWAS approach has been the identification of new candidate genes that 
otherwise would not have been considered of any special interest, these studies have 
failed to provide support for perhaps most of the associations reported in earlier 
candidate gene studies, including MYO9B investigated in this thesis. GWASs have 
therefore also helped to resolve many of these claimed, but debatable associations at 
candidate genes, and have set more widely accepted criteria for declaring association. 
 
But what do all these recent genetic findings tell us about MS? Majority of the genes 
that have emerged in MS GWASs have immunological functions, with the presence 
of T cell related genes being particularly evident, but not much more can be 
concluded from genetic studies alone (IMSGC and WTCCC2 2011). Many of the 
identified candidate genes, including CXCR4 in which a previously suggested 
association was replicated in this thesis, play a role in various processes and it will 
be a challenge to understand in detail how these individual genes contribute to MS 
susceptibility. Studies correlating the identified genetic variants with gene 
expression and cellular functions in different cell types will be needed to investigate 
the potential underlying mechanisms. 
 
Meanwhile, data from existing expression studies comparing gene expression in MS 
cases and controls can provide further clues towards mechanisms of MS 
pathogenesis. In this thesis a systematic review of seven such studies showed that 
genes identified in at least two studies were associated with cytokine pathways 
related to Th2, Th17 and Treg cells. These findings are consistent with increasing 
supporting evidence for the role of Tregs and Th17 cells in MS (Matusevicius et al. 
1999, Viglietta et al. 2004, Segal 2010) and with studies questioning the central role 
of Th1 cells (Ferber et al. 1996, Harrington et al. 2006). It was also shown in this 
thesis that a neutrophil-related gene DEFA1A3 encoding alpha defensins 1 and 3 had 
highly elevated levels in MS patients. Interestingly, this gene has also been found to 
be highly expressed in SLE, T1D and IBD suggesting that the largely ignored 
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neutrophils and this cytotoxic protein in particular could be relevant for autoimmune 
disease pathogenesis. 
 
However, whether these findings from expression studies reflect primary or 
secondary events is a more difficult issue to resolve; many genes and pathways 
become activated after disease onset as the primary event initiating an auto-reactive 
response results in activation of other components of the immune system. That is not 
to say, however, that these secondary events are not relevant in MS as some of these 
are likely to contribute to demyelination and chronic inflammation in MS. Therefore, 
characterizing not only the causes of MS but also these secondary processes is 
highly important from the perspective of developing new treatments. In this thesis 
very little overlap was found in genes identified in expression studies and genes 
identified in GWASs, which may suggest that most of the genes identified in these 
expression studies are not involved in processes that affect susceptibility to MS. 
However, it should be noted that most of the expression studies were conducted in 
small samples and given that there was little overlap between genes identified in 
these studies, majority of the genes reported to be differentially expressed in MS 
may have been false positives rather than MS-related. Much larger samples would 
be needed to decrease the false positive rate and to increase the power to detect true 
signals in expression studies, which are more prone to noise due to effects of 
technical and biological factors than studies on DNA variants. 
 
Finally, although identifying novel candidate genes is always an important step 
forward, it should be noted that interpretation of these findings is limited and driven 
by available data on functions of the identified genes and by the current 
understanding of basic immunology. New immune cell subsets are constantly being 
characterized and previously unknown roles are associated with genes as they are 
being investigated in different cell populations and tissues. While our hypotheses 
and thinking are naturally influenced by existing knowledge, we should not forget 
that in complex diseases and MS anything is possible - at least until proven 
impossible. 
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6 Conclusions and future 
prospects 
In this thesis the aim was to identify MS-related genes and pathways by 
investigating common genetic variants in selected candidate genes through genome-
wide screening of gene expression in PBMCs from MS patients and controls and by 
systematically reviewing previous microarray studies. As a result of these studies it 
was shown that: 
 
I. Expression of DEFA1A3 was highly elevated in MS patients in two 
independent study samples. Increased levels have also previously been 
found in MS and other autoimmune diseases, suggesting a role for 
neutrophils and innate defense mechanisms in the pathogenesis of 
autoimmunity.  
II. Findings from seven genome-wide expression studies in MS show relatively 
little overlap. However, altered expression of 229 genes had been reported 
in at least two studies, of which HSPA1A was reported in four studies. 
III. Genes showing altered expression in MS are associated with several 
immunological pathways including the glucocorticoid receptor signaling 
pathway and Th2-, Th17- and Treg-related interleukin signaling pathways. 
IV. Of 17 genes with altered expression in MS and harbouring confirmed or 
suggestively associated MS risk variants, only CXCR4 and SAPS2 showed 
evidence of correlation between the associated SNP and gene expression. 
V. Consistent with previous data, the variant upstream of CXCR4 was shown 
to be strongly associated with MS and is likely to be a true disease risk 
variant. 
 
Despite considerable progress in MS genetics during the past few years, MS remains 
perhaps one of the most enigmatic of complex diseases. While it is likely that most 
common risk variants with moderate effects have now been identified, a 
considerable fraction of the genetic component still remains unexplained by the 
current findings. But how much of the missing heritability is explained by additional 
common variants with more modest effects and how much can be contributed to rare 
variants with potentially larger effects on risk? The rarity of extended MS families 
in most populations and lack of consistent and strong findings in linkage studies 
would perhaps argue against a major role of rare variants in MS. However, families 
with high MS prevalence do exist and rare variants may play a larger role in such 
cases than in sporadic MS. Importantly, lack of consistent linkage signals across 
populations is not inconsistent with family- and population-specific variants. In fact, 
 THL  –- Research 65/2011 86 Studies on causes of  multiple sclerosis 
 
it is likely that locus and allelic heterogeneity is an important factor in MS and other 
complex diseases, where possibly hundreds of genes and several different pathways 
as well as gene-gene and gene-environment interactions might have an effect on 
disease susceptibility. With lowering costs of re-sequencing, families with multiple 
MS patients are likely to be the first to be investigated. Even if rare variants would 
not play a major role in the majority of sporadic cases, their identification may give 
novel insights into MS pathogenesis. 
 
In addition to rare variants, the role of CNVs in MS remains to be comprehensively 
studied. However, recent evidence suggests that common CNVs do not play a major 
role in complex traits (Conrad et al. 2010). Furthermore, many of the CNVs 
correlate with SNPs and would therefore have been indirectly detected in GWASs. It 
therefore now seems unlikely that common CNVs would end up explaining much of 
the missing heritability in MS. 
 
Finally, in addition to inherited DNA variants, the role of epigenetics and somatic 
and de novo mutations needs to be investigated. A recent study sequencing the 
CD4+ T cell methylome in three MS discordant MZ twin pairs did not reveal any 
consistent and significant methylation differences, which would indicate that at least 
in these cells methylation variation is not a major factor influencing MS (Baranzini 
et al. 2010). The same study also failed to find any mutations and transcriptome 
differences that could have explained the discordance in these genetically ”identical” 
individuals. Similar studies in larger samples and different immunological cell 
populations should however be conducted in order to confirm these initial 
observations. 
 
Although the hunt for missing heritability continues, the primary goal should be to 
understand the disease and its pathogenesis so that more efficient treatments can be 
developed. Functional studies on the currently established MS candidate genes may 
already provide important clues towards achieving this goal, while identifying 
biomarkers or molecular profiles correlating with drug response could also improve 
the safety and efficiency of existing treatments. With the remarkable recent progress 
in MS research, the future is at last looking promising.  
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